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INTRODUCTION1 
 Multi-particulate drug delivery systems are mainly oral dosage forms 
consisting of a multiplicity of small discrete units, each exhibiting some desired 
characteristics. In these systems, the dosage of the drug substances is divided in to 
number of subunit, typically consisting of thousands of spherical particles with 
diameter of 0.05-2.00mm. Thus multiparticulate dosage forms are pharmaceutical 
formulations in which the active substance is present as a number of small 
independent subunits. To deliver the recommended total dose, these subunits are 
filled into a sachet and encapsulated or compressed into a tablet. The purpose of 
designing multiparticulate dosage form is to develop a reliable formulation that has 
all the advantages of a single unit formulations and yet devoid of the danger of 
alteration in drug release profile and formulation behavior due to unit to unit 
variation, change in gastro-luminal pH and enzyme population1 
ADVANTAGES OF MULTIPARTICULATE DRUG DELIVERY 
SYSTEMS1,2 
 Increased bioavailability 
 Reduced risk of systemic toxicity 
 Reduced risk of local irritation 
 Less gastric emptying time 
 Less inter & intra subject variability 
 Uniform drug absorption 
 It provides uniform functional coating  
 
 Multiparticulates are discrete particles that make up a multiple unit 
system. They provide many advantages over single-unit systems because of their 
small size. Multiparticulates are less dependent on gastric emptying, resulting in less 
inter and intra-subject variability in gastrointestinal transit time. They are also better 
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distributed and less likely to cause local irritation. Much emphasis is being laid on 
the development of multiparticulate dosage forms in preference to single unit 
systems because of their potential benefits such as increased bioavailability, reduced 
risk of systemic toxicity, reduced risk of local irritation and predictable gastric 
emptying.  
 There are many reasons for formulating a drug as a multiparticulate 
system for example, to facilitate disintegration in the stomach, or to provide a 
convenient, fast disintegrating tablet that dissolves in water before swallowing 
which can aid compliance in older patients and children After disintegration which 
occurs within a few minutes often even within seconds, the individual subunit 
particles pass rapidly through the GI tract. If these subunits have diameters of less 
than 2mm, they are able to leave the stomach continuously, even if the pylorus is 
closed. These results in lower intra and inter individual variability in plasma levels 
and bioavailability. 
 Drug safety may also be increased by using multiparticulate dosage 
forms, particularly for modified release systems. For example, if the film coat of a 
single-unit enteric coated tablet is damaged, the complete dose will be released into 
the stomach where it may cause pain or ulceration or reduced efficacy, depending on 
the reason for choosing the protection of the enteric coating. Equally, if there is 
damage to the film coating of a monolithic tablet with a sustained release 
formulation, this can lead to “dose dumping” and result in dramatic side effects. By 
contrast, in multiparticulate formulation, the release characteristics are incorporated 
into every single subunit and any damage only affects the release behaviour of the 
subunit involved, which represents a small part of the total dose, reducing the 
likelihood of safety problems. 
 Multiparticulates have a much lower risk of dose dumping than tablets 
single doses that are released accidentally (e.g., by fat) may cause higher incidence 
of adverse events, compared with multiple units,Because they are small and easy to 
swallow, multiparticulates are particularly suited to geriatric formulations 
&paediatric formulations. If a patient breaks a tablet in half so that he or she can 
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swallow it more easily, the tablet's coating layer often is compromised and it can no 
longer provide controlled drug release. Multiparticulates avoid this difficulty 
because they are small enough for geriatric patients to swallow them easily.  
 Dividing a dose into many multiparticulates helps distribute the drug 
slowly, evenly, and consistently. At any given time, multiparticulates are present in 
the stomach, the intestine, and other sites in the GI tract, which helps maximize drug 
absorption. Because multiparticulatesprovide smooth transit through the GI tract and 
are less dependent on gastric emptying, they greatly reduce the variability between 
patients' plasma profiles.  
 Multiparticulates size limits the exposure of the drug to the epithelium 
and reduces the possibility of irritating the GI tract and the bowel. 
 Multiparticulates can be used to improve convenience and patient 
compliance, too. For example, a manufacturer might choose to develop a 
formulation as a traditional tablet because it would allow the company to reach the 
patient relatively quickly. Afterward, the manufacturer could develop a 
multiparticulate dosage form of the same drug to provide modified release for 
increased bioavailability or once-daily application 
 In addition, multiparticulates can allow drug makers to provide patients 
with individualized dosing. For example, a company could package the pellets in a 
device that patients press to dispense individualized doses. A patient thus could take 
the appropriate dose for his or her weight or age group. And a dosage form that 
included instant- and extended-release multiparticulates could improve compliance 
by reducing the number of doses the patient must take each day 
 A generally accepted view is that multiparticulate systems perform better 
in vivo than single unit systems, as they spread out throughout the length of the 
intestine causing less irritation 
 Since multiparticulates enable good control of drug release, the dosage 
form is becoming more popular for drugs that treat chronic conditions. For these 
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reasons, cardiovascular drugs and blood-pressure medicines could benefit from 
multiparticulates. 
 
DISADVANTAGES 
 Low drug loading 
 Proportionally higher need for excipients 
 Lack of manufacturing reproducibility and efficacy 
 Large number of process variables 
 Multiple formulation steps 
 Higher cost of production 
 Need of advanced technology 
 Trained/skilled personal needed for manufacturing 
 Multiparticulates are discrete particles that make up a multiple unit 
system. They provide many advantages over single-unit systems because of their 
small size. Multiparticulates are less dependent on gastric emptying, resulting in less 
inter and intra-subject variability in gastrointestinal transit time. They are also better 
distributed and less likely to cause local irritation3. 
 Much emphasis is being laid on the development of multiparticulate 
dosage forms in preference to single unit systems because of their potential benefits 
such as increased bioavailability, reduced risk of systemic toxicity, reduced risk of 
local irritation and predictable gastric emptying.  
 There are many reasons for formulating a drug as a multiparticulate 
system for example, to facilitate disintegration in the stomach, or to provide a 
convenient, fast disintegrating tablet that dissolves in water before swallowing 
which can aid compliance in older patients and children After disintegration which 
occurs within a few minutes often even within seconds, the individual subunit 
particles pass rapidly through the GI tract. If these subunits have diameters of less 
than 2 mm, they are able to leave the stomach continuously, even if the pylorus is 
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closed. These results in lower intra and inter individual variability in plasma levels 
and bioavailability. 
  Drug safety may also be increased by using multiparticulate dosage 
forms, particularly for modified release systems. For example, if the film coat of a 
single-unit enteric coated tablet is damaged, the complete dose will be released into 
the stomach where it may cause pain or ulceration or reduced efficacy, depending on 
the reason for choosing the protection of the enteric coating. Equally, if there is 
damage to the film coating of a monolithic tablet with a sustained release 
formulation, this can lead to “dose  dumping” and result in dramatic side effects. By 
contrast, in multiparticulate formulation, the release characteristics are incorporated 
into every single subunit and any damage only affects the release behaviour of the 
subunit involved, which represents a small part of the total dose, reducing the 
likelihood of safety problems. 
 Multiparticulates have a much lower risk of dose dumping than tablets 
single doses that are released accidentally (e.g., by fat) may cause higher incidence 
of adverse events, compared with multiple units,Because they are small and easy to 
swallow, multiparticulates are particularly suited to geriatric formulations 
&paediatric formulations. If a patient breaks a tablet in half so that he or she can 
swallow it more easily, the tablet's coating layer often is compromised and it can no 
longer provide controlled drug release. Multiparticulates avoid this difficulty 
because they are small enough for geriatric patients to swallow them easily.  
 Dividing a dose into many multiparticulates helps distribute the drug 
slowly, evenly, and consistently. At any given time, multiparticulates are present in 
the stomach, the intestine, and other sites in the GI tract, which helps maximize drug 
absorption. Because multiparticulates provide smooth transit through the GI tract 
and are less dependent on gastric emptying, they greatly reduce the variability 
between patients' plasma profiles.  
 Multiparticulates size limits the exposure of the drug to the epithelium 
and reduces the possibility of irritating the GI tract and the bowel. 
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Multiparticulates can be used to improve convenience and patient compliance, too. 
For example, a manufacturer might choose to develop a formulation as a traditional 
tablet because it would allow the company to reach the patient relatively quickly. 
Afterward, the manufacturer could develop a multiparticulate dosage form of the 
same drug to provide modified release for increased bioavailability or once-daily 
application 
 In addition, multiparticulates can allow drug makers to provide patients 
with individualized dosing. For example, a company could package the pellets in a 
device that patients press to dispense individualized doses. A patient thus could take 
the appropriate dose for his or her weight or age group. And a dosage form that 
included instant- and extended-release multiparticulates could improve compliance 
by reducing the number of doses the patient must take each day 
 A generally accepted view is that multiparticulate systems perform better 
in vivo than single unit systems, as they spread throughout the length of the intestine 
causing less irritation. Since multiparticulates enable good control of drug release, 
the dosage form is becoming more popular for drugs that treat chronic conditions. 
For these reasons, cardiovascular drugs and blood-pressure medicines could benefit 
from multiparticulates. 
MECHANISM OF DRUG RELEASE FROM MULTI-
PARTICULATES1  
 The mechanism of drug release from multiparticulates can be occur in the 
following ways: 
Diffusion 
 On contact with aqueous fluids in the gastrointestinal tract (GIT), water 
diffuses into the interior of the particle. Drug dissolution occurs and the drug 
solutions diffuse across the release coat to the exterior. 
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Erosion 
 Some coatings can be designed to erode gradually with time, thereby 
releasing the drug contained within the particle. 
Osmosis 
 In allowing water to enter under the right circumstances, an osmotic 
pressure can be built up within the interior of the particle. The drug is forced out of 
the particle into the exterior through the coating  
 
 
MAKING MULTIPARTICULATES 
Fluid-bed processor 
 The simplest manufacturing technique is to layer the liquid drug onto 
inert spherical particles made of sugar or microcrystalline cellulose this process is 
done using a bottom spray with a Wurster column attachment on a fluid-bed 
processor.  
Extrusion and Spheronization 
 Another common manufacturing method relies on extrusion and 
spheronization. First, operators force a blended, wet mass of drug and excipients 
through aporous plate with an extruder. Then the fragments are loaded onto a 
revolving disk with a chosen surface roughness, and the disk's rotation forms 
rounded pellets.  
Spray Congealing 
 In hot-melt spray congealing, scientists melt a waxy polymer and mix an 
API into it, The API must be thermally stable enough to withstand the polymer's 
melting temperatures of 60–70 °C. Droplets of this molten mixture fall onto a fast-
rotating disc and are dispersed into fine particles that solidify as they travel, within 
several centimeters. These fine particles become spherical multiparticulates that can 
be encapsulated and used for modified release.  
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Centrifugal coating granulator  
 It is based on layering the drug directly in powdery form where drug 
loading occurs by gravity and adhesion is ensured by a liquid binder sprayed onto 
the cores. The layering process is particularly suitable for production of small drug 
loaded units, multiples of which are placed into capsules for patient delivery. 
DESIGN OF MULTIPARTICULATE DRUG DELIVERY 
SYSTEMS1 
Intestinal Protective Drug Absorption System 
 Intestinal protective drug absorption system (IPDAS) (Figure1) is a 
multiparticulate tablet technology that hasbeen developed to enhance the gastric 
tolerability of potentially irritant or ulcerogenic drugs such as the NSAIDs. 
 
Fig 1: Intestinal Protective Drug Absorption System 
 It consists of high density controlled release beads that are compressed 
into a tablet form. The beads may be manufactured by techniques such as extrusion 
spheronization and controlled release can be achieved with the use of different 
polymer systems to coat the resultant beads. Alternatively, the drug can also be 
coated into on an inert carrier such as non-pareil seeds to produce instant release 
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multiparticulates. Controlled release can be achieved by the formation of a 
polymeric membrane on to these instant release multparticulates. 
 Once an IPDAS tablet is ingested; it rapidly disintegrates and disperses 
beads containing the drug in the stomach which subsequently pass into the 
duodenum and along the gastrointestinal tract in a controlled and gradual manner, 
independent of the feeding state. Release of active ingredient from the 
multiparticulates occurs through a process of diffusion either through the polymeric 
membrane and /or the micro matrix of the polymer/active ingredient formed in the 
extruded/spheronizedmultiparticulates. The intestinal protection of IPDAS is by 
virtue of the multiparticulate nature of the formulation which ensures wide 
dispersion of irritant drug throughout the gastrointestinal tract4. 
Spheroidal oral drug absorption systems 
Spheroidal Oral Drug Absorption System (SODAS) (Figure 2) is a multiparticulate 
technology that enables the production of customized dosage forms and responds 
directly to individual drug candidate needs. It can provide a number of tailored drugs 
release profiles including immediate release of drug followed by sustained release to give 
rise to a fast onset of action which is maintained for 24 hours. Alternatively, the opposite 
scenario can     be achieved where drug release is delayed for a number of hours5.                             
 
 
Fig 2: Spheroidal Oral DrugAbsorption System 
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Programmable Oral Drug Absorption System 
Programmable Oral Drug Absorption System (PRODAS) (Figure 3) is presented as 
a number of mini tablets contained in hard gelatin capsule. It thus combines the 
benefits of tableting technology within a capsule. It is possible to incorporate many 
different minitablets, each one formulated individually and programmed to release 
drug at different sites within the GIT. These combinations may include immediate 
release, delayed release, and/or controlled release mini tablets. It is also possible to 
incorporate mini tablets of different sizes so that high drug loading is possible. Their 
size ranges usually from 1.5 – 4 mm in diameter6.        
 
Fig 3: Programmable Oral Drug Absorption  System 
Diffucaps7: 
 In this multiparticulate system, drug profiles are created by layering an 
active drug onto a neutral core such as sugar spheres, crystals or granules followed 
by the application of a rate-controlling, functional membrane (Figure 4). The coating 
materials can be water soluble, pH dependent or independent or water insoluble 
depending on the individual needs of compound. The resultant beads are small in 
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size approximately 1mm or less in diameter. By incorporating beads of differing 
drug release profiles into hard gelatin capsules, combination release profiles can be 
achieved. It is possible to customize any combination of sustained release, pulsatile 
release and immediate release profiles depending on the specific needs of the 
product. The drug layering process can be conduct either from aqueous or solvent 
based drug solutions.  
  
     Fig 4: Diffucaps 
 Diffucaps beads are small in size, approximately 1mm in diameter, and 
are filled into a capsule to create the final dosage form. Beads of differing drug 
release profiles can be easily combined in a single capsule providing high levels of 
control over release profiles. Diffucaps beads of different drugs can be combined to 
make convenient single dose units for combination therapies. 
 Diffucaps consist of different layers, The number of layers and its nature 
depend on the nature of formulation and nature of drug. a typical diffucaps consist of 
a core material spherical in shape called non peril seeds .A core material of uniform 
size and of spherical in shape is needed to do uniform coating.  Over the core the 
drug is layered with uniform thickness. The drug layer is further covered by a barrier 
which prevent the direct interaction of drug with polymer used for modified release. 
The functional coating is done over the barrier coated pellets to get the desired 
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modified release pattern. Over the function coating an optional top coating is done to 
get the  moisture protection, & lubrication.   
Mini-Tablets 
The MINITABS technology (Figure 5) is unique in that it offers the 
advantages of a tablet combined with those of a multiparticulate drug form they are 
tiny (2mm x 2mm) tablets containing gelforming excipients that control drug release 
rate. Additional membranes may be added to further control releaserate. The small 
size of minitabs means that they can be filled into capsules as a final dosage form. 
As a result, combination products can be developed to allow for two or more release 
profiles within a single capsule. Minitabs offer high drug loading, the ability to fine 
tune release rates for targeted delivery andcontent uniformity for more accurate 
dosing. Minitabs offer high drug loading, a wide range of release rate designs, and 
fine tuning of these release rates. The capsules can be opened and the contents used 
as a "sprinkle" formulation8.  
 
Fig 5:Minitabs 
 It is a widely acceptable statement that solid oral dosage forms, mainly 
tablets are most acceptable form for delivering medication. There are some new 
variations emerging such as mini-tablets, offering formulation flexibility. Mini-
tablets are small tablets with diameter equal to or less than3mm that are filled in 
capsule, or at times compressed into tablets. It is possible to incorporate many 
different mini-tablets each designed to release drug at different sites within the GIT. 
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The combinations may include IR, DR and/or CR .  It is possible to incorporate 
different drugs in mini-tablets used for concurrent disease or combination of drugs 
to improve therapeutic outcome, while delivering release rates of each accordingto 
disease needs. It can also offer a good solution for various problems faced currently 
in pharmaceutical industry representing a lack of dosage forms which are suitable 
for pediatrics. 
                Mini-tablets combine the established tableting technology with the 
multiparticulate dosage forms. Additional benefits are regular shape, excellent size 
uniformity, and smooth surface therebyoffering best substrate for coating with 
different polymer materials. Mini-tablets can be produced by DC or wet or dry 
granulation and can be manufactured by normal tableting machines with only 
minorequipment modifications. For example, to increase the production speeds, 
multiple tip tooling has beenemployed routinely. It can also be coated using 
perforated coating pan or a fluid bed apparatus9  
 
Fig 6: Mini-tablets with die, upper and lower punch10. 
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Fig 7: Mini-tablets delivered (a) as a tablet or a (b) capsule11  
 Mini-tablet is a good substitute for pellets because they can be easily 
manufactured and are also favors coating in order to produce sustain drug release. 
Further, dosage forms containing mini-tablets are smaller when compared to 
granules and pellets. Hence, developing mini-tablets for controlled drug release for 
oral route is the important focus in the research field. Likewise, matrix mini-tablet 
has also been developed.  
 Several mini-tablets can be placed in a capsule; hence tablets with 
different content, dose and release characteristics can be included. Inclusion of 
IRMT permits the development of rapid acting EMT dosage forms with optimal 
pharmacokinetic profiles for rapid action. In EMT various sustained drug release 
profiles can be designed by combining different quantities of mini-tablets, and can 
also include combination of different drugs, thereby improving patient compliance. 
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To bring about immediate release, IRMT contained low substituted HPC as a 
disintegrant, and were prepared by simply coating mini-tablets with HPMC. 
 The SRMT is coated with a mixture of EC and HPMC. Mixtures of 
polymers were used for controlled release drug delivery system to allow pore-
mediated diffusion through the film.12 
 The advantages of SRMT over single unit dosage forms are 
 Less risk of dose dumping 
 Less intra and inter subject variability 
 Child acceptability 
 Dosing flexibility 
 Taste masking 
 High degree of dispersion in  GIT thus minimizing the risk of high 
local drug concentrations13 
 Excipient tolerability for drug substance with bitter taste or 
potential chemical instability in liquid10  
Advantages  
 Mini-tablets pack large quantity of API in a form that can be easily 
swallowed.  
 Due to its small size, it can quickly and uniformly pass through the 
stomach, and is also independent of meals 
 Good alternative to pellets and easier to manufacture 
 Manufacturing different doses in one tablet forming step and filled 
into capsule according to dose 
 This brings up the opportunity to combine tablets with different 
coating in one capsule14 
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 It’s an easy way to produce complex release profiles, i.e. initial and 
maintenance dose in one capsule lowers the risk of dose dumping 
 Several chemically incompatible drugs pressed into mini-tablets, 
coated and combined in one capsule. 
 Mini-tablets also offers an alternative for pellets because of their 
ease of manufacture, because of dosage forms of equal dimension 
and weight with smooth regular surface are produced in a 
reproducible and continuous way13  
Stabilized Pellet Delivery System: 
 Stabilized pellet delivery system technology uses functional polymers or 
a combination of functional polymers and specific additives, such as composite 
polymeric materials to deliver a drug to a site of optimal absorption along the 
intestinal tract. The active drug is incorporated in multiparticulate dosage forms such 
as DIFFUCAPS or Eurand MINITABS, which are then subsequently coated with pH 
dependent/independent polymeric membranes that will deliver the drug to the 
desired site. These are then filled into hard gelatin capsules. This technology is 
designed specifically for unstable drugs and incorporates a pellet core of drug and 
protective polymer outer layer(s)1 
Pelletized Delivery System: 
 Pelletized Delivery System (PDS) is a sustained release system using 
pellets or beads manufactured using arumerization/ pheronization/ pelletization 
techniques or by layering powders or solutions on nonpareil seeds. Release 
modulating polymers are sprayed on the beads using various coating techniques. The 
coated beads are filled in to hard gelatin capsules. Drug release occurs by diffusion 
associated with bioerosion or by osmosis via the surface membrane. The release 
mechanism can be pH-activated or pH-independent. The beads can be formulated to 
produce first order or zero order release.1 
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Pelletised tablet: 
 Pelletised tablet (Peltab®) system utilizes polymer-coated drug pellets or 
drug crystals,which are compressed into tablets. In order to provide a controlled 
release, a water insoluble polymer is used to coat discrete drug pelletsor crystals, 
which then can resist the action of fluids in the GIT. This technology incorporates a 
strong polymer coating enabling the coated pellets to be compressed into tablets 
without significant breakage1. 
Multiparticle Drug Dispersing Shuttle: 
 Multiparticle drug dispersing shuttle (Multipart®) consists of a tablet 
carrier for the delivery of controlled release beads or pellets through the GIT which 
preserves the integrity and release properties of the beads. The distribution of the 
beads is triggered by the disintegration of the tablet carrier in the stomach. Drug 
release from the beads is triggered by super disintegration of the tablets. It can be 
pH-activated or pH-independent and can occur by disintegration or osmosis. The 
beads can be formulated to produce first or zero order release1. 
Macrocap®: 
 Macrocap® consists of immediate release beads made by extrusion/ 
spheronization/ pelletization techniques or by layering powders or solutions on 
nonpareil seeds. Release modulating polymers are sprayed on the beads using 
various coating techniques. The coated beads are filled in hard gelatin capsules. 
Drug release occurs by diffusion associated with bioerosion or by osmosis via the 
surface membrane. The release mechanism can be pH-activated or pH independent. 
The beads can be formulated to produce first or zero order release1. 
Orbexa®: 
 Orbexa® technology is a multiparticulate system that enables high drug 
loading and is suitable for products that require granulation. This technology 
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produces beads that are of controlled size and density using granulation, extrusion 
and spheronization techniques. This process is unique in that it allows for higher 
drug loading than other systems, is flexible and is suitable for use with sensitive 
materials such as enzymes1. 
KV/24: 
 KV/24 is a patented, multiparticulate drug delivery technology that 
encapsulates one or more drug compounds to achieve release in a pre-determined 
fashion over a 24-hour period after oral administration. KV/24 technology is based 
upon coating a neutral core (nonpareiled bead) with a drug substance, then 
sequentially coating with one or more polymers to achieve a once-a day release 
profile. The drug can either be combined with the neutral core or incorporated into 
the coating process1.  
Flashtab: 
 Flashtab technology is a fast dissolving/disintegrating oral tablet 
formulation. It is a combination of taste masked multiparticulate active drug 
substances with specific excipients compressed into tablets. A disintegrating agent 
and a swelling agent are used in combination with coated drug particles in this 
formulation to produce a tablet that disintegrates in the mouth in less than one 
minute. These oro-dispersible tablets disperse rapidly before the patient swallow 
them1. 
DELAYED RELEASE FORMULATION 
 The United States Pharmacopeia (USP) defines delayed-release tablets 
as enteric-coated to delay release of the medication until the tablet has passed 
through the stomach to prevent the drug from being destroyed or inactivated by 
gastric juices or where it may irritate the gastric mucosa15. 
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Figure 8: Comparative dissolution profile of an immediate release and modified 
release formulations 
 
 
 
 
 
 
 
 Delayed release dosage forms redesigned to release the drugs at a time 
rather rapidly after administration the delay may be time based or based on influence 
of physiological conditions like G.i.t pH. 
 Drugs contained in such a system are those that are 
1. Destroyed in the stomach 
2. Destroyed by the intestinal enzymes 
3. Known to cause gastric distress 
4. Absorbed from specific intestinal site 
5. Meant to exert local effect at a specific gastrointestinal site 
 Types of delayed release systems 
1. Intestinal release systems 
2. Colonic release systems 
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INTESTINAL RELEASE SYSTEMS 
A drug may be enteric coated for intestinal release  to prevent destabilization 
in gastric pH or to release the drug in intestinal pH16. 
COLONIC RELEASE SYSTEMS 
 Drugs are poorly absorbed through colonmay be delivered to such a site 
for 2 reasons  
1. Local action in the treatment of ulcerative colitis 
2. Systemic absorption of protein and peptide drugs 
 Advantage is taken of the fact that pH sensitive bio-erodible polymers 
like polymethacrylates release the medicaments only at the alkaline pH of the colon 
or use of divinyl benzene cross linked polymers that can be cleaved only by the 
azoreductase of the colonic bacteria to release the free drug for local effect or 
systemic absorption. The most commonly used pharmaceutical delayed releaser 
solid oral dosage forms include capsules, tablets, granules and pellets17 
 Enteric coating18  
 An enteric coating is a barrier applied to oral medication that controls 
the location in the digestive system where it is absorbed. Enteric refers to the small 
intestine; therefore enteric coatings prevent release of medication before it reaches 
the small intestine. 
 Most enteric coatings work by presenting a surface that is stable at the 
highly acidic pH found in the stomach, but breaks down rapidly at a less acidic 
(relatively more basic) pH. For example, they will not dissolve in the acidic juices of 
the stomach (pH ~3), but they will in the higher pH (above pH 5.5) environment 
present in the small intestine. Materials used for enteric coatings include fatty acids, 
waxes, shellac and plastics, plant fibers. 
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Advantages of enteric coating19,20:  
 To protect drugs that are unstable in acid from disintegrating in 
thegastric juices (e.g., antibiotics, enzymes, peptides, proton pump 
inhibitors) 
 To protect the stomach from aggressive drugs that irritate the 
gastricmucosa (e.g., acetylsalicylic acid, iron compounds) 
 pH-dependent controlled release of drugs for optimal absorption 
 Delayed release 
 GI targeting of different sections of the small intestine or of the 
colon(absorption window, targeting localized effects 
 Colon targeting for local treatment and systemic therapies 
 Solid dosage forms containing drugs that are susceptible to degradation 
in the stomach due to the acidic environment or gastric enzymes have been 
stabilized with an enteric film coating. Enteric coating has traditionally been used to 
prevent drug release in the upper GI tract.  A decrease in gastric irritation caused by 
drugs, such as aspirin, can also be achieved by enterically coating the solid dosage 
form.In addition, enteric coatings can be used to target drug release in the small 
intestine. 
Ideal characteristics of enteric coating polymers 
1. Resistance to gastric fluids 
2. Ready susceptibility or permeability to intestinal fluids 
3. Compatibility with most coating solution components and the drug 
substrates 
4. Non toxicity  
5. Formation of continuous film 
6. The film should not change on aging 
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7. Low cost 
8. Ease of application 
ENTERIC POLYMERS USED FOR FILM COATING OF SOLID 
DOSAGE FORMS21 
 Enteric polymers currently used to coat pharmaceutical dosage forms 
include cellulose, vinyl, and acrylic derivatives. These polymers exhibit resistance to 
gastric fluids yet are readily soluble or permeable in intestinal fluid. Enteric 
polymeric materials are primarily weak acids containing acidic functional groups, 
which are capable of ionization at elevated pH. In the low pH of the stomach, the 
enteric polymers are unionized, and therefore, insoluble. As the pH increases in the 
intestinal tract, these functional groups ionize, and the polymer becomes soluble in 
the intestinal fluids. Thus, an enteric polymeric film coating allows the coated solid 
to pass intact through the stomach to the small intestine, where the drug is then 
released for absorption through the intestinal mucosa into the human body where it 
can exert its pharmacologic effects. 
Cellulose acetate phthalate (CAP) 
 The CAP polymer exhibits rapid dissolution at a pH greater than 6 and is 
relatively permeable to moisture and gastric juices. Due to its high moisture 
permeability, CAP is susceptible to hydrolytic decomposition. Phthalic and acetic 
acid molecules may hydrolyze during storage and significantly compromise the 
degree of enteric protection that the film coating provides. The addition of a 
plasticizing agent has been shown to improve the water resistance of CAP films 
Polyvinyl acetate phthalate (PVAP) 
 PVAP is another enteric polymer commonly used to coat solid dosage 
forms .This polymer is structurally similar to CAP containing the 
dicarboxylicpthalic acid in a partially esterified form. Faster release of drug 
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components occurs with PVAP because dissolution of this polymer occurs at a pH 
of approximately 5.0. Due to its lower moisture permeability. 
Hydroxypropyl methylcellulose phthalate (HPMCP) 
 Esterified HPMC with pthalic anhydride to produce hydroxypropyl 
methylcellulose phthalate (HPMCP), which rapidly dissolves in the upper intestinal 
tract. Due to the limited compatibility of HPMCP with several types of plasticizers, 
hydroxypropyl methylcellulose acetate succinate (HPMCAS) was developed. The 
presence of ionizable carboxyl groups in the HPMCAS structure cause the polymer 
to solubilize at high pH (> 5.5 for the LF grade and > 6.8 for the HF grade). This 
polymer exhibits good compatibility with a variety of plasticizing agents 
Methacrylic acid copolymers 
 Polymethacrylates are synthetic cationic and anionic polymers of 
dimethylaminoethylmethacrylates, methacrylic acid, and methacrylic acid esters in 
varying ratios. These polymers are produced by an emulsion polymerization process 
and are commercially available in several forms. The dissolution properties of these 
polymers are dependent on the content of carboxyl groups in the polymer. These 
acrylic derivatives are commercially available from Eudragit®. Eudragit L 30 D-55 
is an aqueous-based dispersion containing USP/NF methacrylic acid copolymer 
Type C and exhibits dissolution above pH 5.5. Acryl-Eze® is a relatively new fully 
formulated acrylic enteric coating system based on spray-dried USP/NF methacrylic 
acid copolymer Type C, containing plasticizer(s), pigment(s), and neutralizing 
agents in a powder form for redispersion in water. Eudragit FS 30 D is an aqueous-
based acrylic polymeric dispersion consisting of methacrylic acid, methyl acrylate, 
and methyl methacrylate. This polymer contains fewer carboxyl groups and thus 
dissolves at a higher pH (> 6.5). 
 Most commonly used pH-dependent coating polymers for peroral 
delivery are methacrylic acid copolymers, Eudragit L100 and Eudragit S100, which 
dissolve at pH 6.0 and 7.0 respectively. The combination of these two polymers in 
various ratiosmakes it possible to manipulate drug release within 6.0-7.0 pH range. 
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Table No.1 Enteric polymers utilized in development of modified-release 
formulations 
S.NO Enteric polymers 
Optimum pH For 
Dissolution 
1 Polyvinyl acetate phthalate (PVAP)  5 
2 Cellulose acetate trimellitate (CAT)  5.5 
3 Hydroxypropyl methylcellulose phthalate 
(HPMCP) 
>5.0 
 
>5.5 A) HP-50 
B) HP-55 and HP-55S 
4 Hydroxypropylmethylcellulose acetate succinate 
(HPMCAS) 
>5.5 
 
>6.0 
 
>6.8 
A) LF Grade 
B) MF Grade 
C) HF Grade 
5 Methacrylic acid copolymer, Type C (Eudragit® 
L100-55) 
Methacrylic acid copolymer dispersion 
(Eudragit® L30D-55) 
> 5.5 
6 Methacrylic acid copolymer, Type A 
(Eudragit L-100 and Eudragit® L12,5) 
> 6.0 
7 Cellulose acetate phthalate (CAP) (Aquateric®) 6 
8 Methacrylic acid copolymer, Type B 
(EudragitS-100 and Eudragit® S12,5) 
>7.0 
9 Eudragit® FS30D > 7.0 
10 Shellac (MarCoat 125 and 125N)  7 
11 Acryleze MP 7 
12 NS Enteric Surelase 7.3 
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LITERATURE REVIEW 
 NS Dey, S Majumdar and MEB Rao et al., (2008)1  reviewed on 
multiparticulate drug delivery systems. They are especially suitable for achieving 
controlled or delayed release oral formulations with low risk of dose dumping, 
flexibility of blending to attain different release patterns as well as reproducible and 
short gastric residence time. The release of drug from microparticles depends on a 
variety of factorsincluding the carrier used to form the multiparticles and the amount 
of drug contained in them. Consequently,multiparticulate drug delivery systems 
provide tremendous opportunities for designing new controlled and delayed release 
oral formulations, thus extending the frontier of future pharmaceutical development 
 Lailafathima Ali sagar et al., (2006)20 studied the in vivo behaviour of 
pellets and reported that the mean gastric emptying time for pellets was very less 
than tablet. And the mean transit through the small intestine did not vary 
significantly for both the formulations. And pellets were having longer residence 
time in large intestine than tablets 
 PareshPrajapati A et al., (2010)22  prepared ocular mini tablets of 
ocular mini tablets by single punch compression machine equipped with 4mm flat 
round tooling specially developed in the lab. Invivo release of drug from ocular mini 
tablets was determined at different dissolution volume and rotational speeds. 3 in 
vitro methods were used for the determination of drugs and their release of drugs 
from various ophthalmic preparations  was determined in rabbit eye and invitro 
release rate of the drug was  determined at different rotational speed. 3 in vitro 
methods were used for the determination of the drugs and their release from various 
ophthalmic preparations by using static method stirred (paddle) method and rotating 
vial method finding correlation coefficient and plotting a scattered diagram 
established in vitro= in vivo relationship by rotating vial method matched with the 
invivo results. Specific hydrodynamic and volume showed high in vitro –in vivo 
correlation  
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 Carla M. Lopes, Jose Manuel Sousa Lobo et al., (2006)11 Compressed 
mini-tablets systems as a biphasic delivery system designed for zero-order sustained 
drug release. The outer layer thatfills the void spaces between the mini-tablets were 
formulated to release the drug in a very short time (fast release), while the mini-
tablets provideda prolonged release. Different composition (HPMC or EC) and 
number (10 or 21) of mini-tablets were used to obtain different drug release 
rates.The in vitro performance of these systems showed the desired biphasic 
behaviour: the drug contained in the fast releasing phase (powder enrobingthe mini-
tablets) dissolved within the first 2 min, whereas the drug contained in the mini-
tablets was released at different rates, depending uponformulation. Based on the 
release kinetic parameters calculated, it can be concluded that mini-tablets 
containing HPMC were particularly suitableapproaching to zero-order (constant) 
release over 8 h time periods. 
 Domenico De Berardis et al., (2007)23 has reviewed to elucidate current 
facts and views about the role of Duloxetine in the treatment of ADs. In February 
2007, duloxetine was approved by FDA for the treatment of generalized anxiety 
disorder (GAD). The results of trials evaluating the use of duloxetine in the 
treatment of GAD was supportive on its efficacy even if further studies on long-term 
use were needed. Apart from some interesting case reports, no large studies were, to 
date, present in literature about duloxetine and other ADs such as panic disorder, 
social anxiety disorder, obsessive-compulsive disorder and post-traumatic stress 
disorder. Therefore, the clinical efficacy and the relative good tolerability of 
duloxetine may be further investigated to widen the therapeutic spectrum of ADs. 
 Timothy Smith et al., (2007)24 did a review article to discuss the 
background of painful diabetic neuropathy, the pharmacology of Duloxetine, and its 
safety and efficacy in clinical trials and long-term observations. The authors also 
commented on its use in clinical practice. Results from controlled clinical trials 
reveal that Duloxetine administered at 60 mg q.d or 60 mg b.i.d was efficacious in 
treating diabetic neuropathic pain relative to placebo. Positive treatment outcomes 
were also seen for other measures of pain and quality of life. A minor but 
statistically significant increase in blood glucose compared with placebo treated 
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patients has been observed in controlled clinical trials. Otherwise, controlled and 
open-label clinical studies have demonstrated a high degree of safety and tolerability 
for the compound. These findings provide support for the proposed role of serotonin 
and nor epinephrine as key mediators of the descending pain inhibition pathways of 
the brain stem and spinal cord 
 Melanie E. Hunziker et al., (2005)25 reviewed the literature on 
Duloxetine with regard to itspharmacodynamics, pharmacokinetics, clinical efficacy, 
and tolerability. A comprehensive search of MEDLINE was performed using the 
terms Duloxetine, Cymbalta, and major depressive disorder, with norestriction on 
year. The Eli Lilly and Company clinical trial registry, and abstracts and posters 
from recentAmerican Psychiatric Association meetings were also reviewed. 
Duloxetine exhibits linear, dose dependent pharmacokinetics across the approved 
oral dosage range of 40 to 60 mg/day. No dose adjustment appears to be needed 
based on age. Duloxetine has shown efficacy in reducing depressive symptoms 
compared with placebo, and Duloxetine recipients have shown significant 
improvements in global functioning compared with placebo (both, P < 0.05). 
Response and remission rates have beencomparable to or greater than those seen 
with Fluoxetine or Paroxetine. Duloxetine was generally well tolerated, with nausea, 
dry mouth, and fatigue being the most common treatment-emergent adverse effects. 
Cardiovascular adverse effects do not appear to result in sustained blood pressure 
elevations, QTc-interval prolongation, or other electrocardiographic changes. 
Conclusions: Based on the availableevidence, Duloxetine was a well-tolerated and 
effective treatment for MDD in adults. Randomized head to-head comparisons 
against established antidepressants were needed to determine the relative safety and 
efficacy of Duloxetine. 
 Muhammad Rashedul Islam et al., (2010)26 did an investigation to 
develop a delayed release pellet dosage form of Duloxetine hydrochloride. Drug 
loaded nuclei was prepared using powder-layering technique in a conventional 
coating pan. The nuclei was coated with an acid resistant acrylic polymer (Eudragit 
L30 D55) in a wurster coater to different thickness equivalent to theoretical polymer 
load 25%, 30%, 35% and 40% w/w on dry basis. The in-vitro dissolution studies 
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were conducted in 0.1N HCl (pH~1.1) for 2 hours followed by phosphate buffer (pH 
6.8) for 1 hour with USP dissolution tester (Type II). Enteric coated pellets with 
polymer load 25% and 30% failed to provide require acid resistant to the pellets but 
very insignificant amount of drug was leached from the coated pellets in acid phase 
with polymer load 35% and 40% in the acidic phase, whereas almost the whole 
amount of drug was released in the buffer phase. The results generated in this study 
showed that proper selection of polymer materials based on their physiochemical 
properties as well as polymer load is important in designing delayed release pellets 
dosage form with acceptable dissolution profile 
 NelePoelvoorde et al., (2009)27 developed themulti-particulate 
formulation of viable bacteria for oral and vaginal delivery usingEudragit® FS30D 
as enteric polymer  & PVA-based coating (Opadry® II and Opadry® AMB) before 
enteric coating as a sub coat. The result concluded that subcoatings have been used 
successfully prevents direct contact between acid-labile drug and the acidic 
functional groups of the enteric coating. The Layered pellets were protected by 
Eudragit® FS30D against the gastric fluid, resulting in an acceptable cell load of 1.4 
× 108 cfu/100 mg after gastric passage 
 V.M. Castano et al., (2008)28 nanoencapsulation of Acetyl Salicylic 
Acid (ASA) was carried out by a modified double emulsion, using an enteric coating 
of the copolymers Eudragit L-100 and L-30-D-55 as polymeric matrix. The best 
results of the nanoencapsulation NPs process were reached with the combination of 
the copolymer Eudragit L-100 and L-30 D-55, showing nanoparticles yield and 
encapsulation efficiency higher than 90% and release profiles with smaller burst. 
The release profiles indicate that the matrix used was suitable to prevent the contact 
of the active principle with the gastric medium and that this device could achieve a 
more efficient release in the intestine. 
 Fude Cui et al., (2007)29 formulated enteric-soluble solid-state emulsion 
to enhance the stability of oily drugs in the gastric fluid. The ESE was prepared by 
spreading liquid o/w-emulsions on a flat glass and drying at the oven maintained at 
400C. Aerosil 200 was applied as solid carrier and emulsifier. Eudragit® L30D-55 
28 
 
Literature Review 
was used as enteric coating material droplet size distribution of the primary 
emulsions and the emulsion after reconstitution of zedoary turmeric oil (ZTO) ESE 
in the phosphate buffer were also measured. When ZTO ESE was immersed into 
phosphate buffer (pH 6.8), the stable emulsion was formed in 20 min, but the release 
was obviously suppressed when it was exposed to the gastric fluid. It was concluded 
that preparation of enteric-soluble solid-state emulsion by the present method for 
oral oily drug was feasible. 
 Pao-Chu Wu et al., (2006)30 studied the effect of eudragit and enteric 
polymer composite on the Release of nicardipine. In this study, the water-insoluble 
polymers such as eudragit RL (RL) and Eudragit RS (RS) were used as retardants to 
prepare the sustained release dosage form of nicardipine/polymer solid dispersion by 
solvent evaporation method. The enteric polymers such as hydroxypropyl 
methylcellulose acetate succinate, LF grade (HPMCAS) and hydroxypropyl 
methylcellulose phthalate, HP-55 grade (HPMCP) were incorporated into the 
drug/polymers solid dispersions to modify the release rate of drug. The effects of the 
sustained release of nicardipine from drug/ Eudragit/enteric polymer solid 
dispersions were evaluated by the dissolution it was found that the dissolution 
efficiencies of drug were increased 2.35-21.08 folds with the addition of 20-40%of 
enteric polymer in pH 6.8 media. 
 Su-Yun Lyu et al., (2004)31 studied the effect of Enteric Coated 
Granules of Mistletoe Lectinresults indicated that Eudragit, produced outstanding 
results with ideal release profiles and only minimal losses of cytotoxicity after 
manufacturing step. 
 S.Bozdağ et al., (1999)19 formulated enteric coated omeprazole tablets 
usingHPMCP Eudragit® S-100, CAP and the study revealed that HPMCP & CAP 
were excellent polymers for  releasing the drug atintestinal pH with least release in 
stomach.  
 Shin Etsu Chemical et al.,  (2006)32 Aqueous Dispersion coating using 
Shin Etsu AQOAT ® preparation of coating dispersion.   
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 Patrick jansen et al., (1998)33 characterised the formation of 
succinamide and phthalamide impurities on interaction of Duloxetine Hcl with 
enteric polymers  such as HPMCAS & HPMCP respectively, and the rate of 
formation is high in accelerated stability conditions. 
 Gang Cheng et al., (2004)34 conducted a study on Time- and pH-
dependent colon-specific drug delivery for orally administered diclofenac sodium 
and 5-aminosalicylic acid DS tablets and 5-ASA pellets were coated by ethyl 
cellulose (EC) and methacrylic acid copolymers (Eudragit® L100 and S100), 
respectively. The in vitro release behaviour of the DS coated tablets and 5-ASA 
coated pellets were examined Release profile of time-dependent DS coated tablets 
was not influenced by pH of the dissolution medium, but the lag time of DS release 
was primarily controlled by the thickness of the coating layer. The thicker the 
coating layer, the longer the lag time of DS release is. 5-ASA release features from 
the coated pellets depended upon both the combination ratio of the Eudragit® L100 
and S100 pH-sensitive copolymers in the coating formulation and the thickness of 
the coating layer. 
 Norihitoshimono et al., (2003)35 a multiparticulate chitosan-dispersed 
system which was composed of the drug reservoir and the drug release-regulating 
layer was developed for drug delivery. Enteric-coated drug coreswere prepared to 
remain intact in the stomach by using Enteric components (EudragitL100-55) and 
then to releasethe active ingredient in the upper small intestine. 
 Sureteric ®36 is a complete aqueous film coating formulation developed 
to meet the delayed release coating needs of solid oral dosage forms in the 
pharmaceutical industry,sureteric was designed for easy preparation, processing and 
clean up. 
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PATENT SEARCH REPORTS37 
US 2008/0317845 A1  
 The patent application shows formulation of Duloxetine formulation 
comprising of core with desired quantity of Duloxetine, a separating layer with 
HPMC and an enteric coating made with HPMCP 
US 2008/0226711 A1 
 The patent application shows development of Duloxetine formulation 
comprising of core coated with desired quantity of Duloxetine, a separating layer on 
the core and an enteric coating made with HPMCP 
US 2010/0040680 A1  
 The patent application shows development of Duloxetine formulation 
comprising of core coated  with desired quantity of Duloxetine, a separating layer on 
the core and an enteric coating made with different enteric polymers which soluble 
at different Ph. 
US 2009/0226517 A1 
 The patent application shows development of Duloxetine formulation 
comprising of core coated with Duloxetine salt form, a separating layer contains an 
amino acid disposed over the drug layer and an outer enteric coating made HPMCP. 
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DISEASE PROFILE 38,39 
INTRODUCTION  
               Depression is a common mental disorder that presents with depressed 
mood, sad and/or irritable mood exceeding normal sadness or grief loss of interest or 
pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, low energy, 
and poor concentration. More specifically, the sadness of depression is characterized 
by a greater intensity and duration and by more severe symptoms and functional 
disabilities than is normal. Depression occurs in persons of all genders, ages, and 
backgrounds. 
 These problems can become chronic or recurrent and lead to substantial 
impairments in an individual's ability to take care of his or her everyday 
responsibilities. At its worst, depression can lead to suicide, a tragic fatality 
associated with the loss of about 850 000 lives every year. 
 Depression is the leading cause of disability as measured by YLDs and 
the 4th leading contributor to the global burden of disease (DALYs) in 2000. By the 
year 2020, depression is projected to reach 2nd place of the ranking of DALYs 
calcuated for all ages, both sexes. Today, depression is already the 2nd cause of 
DALYs in the age category 15-44 years for both sexes combined. 
 Depressive signs and symptoms are characterized not only by negative 
thoughts, moods, and behaviours but also by specific changes in bodily functions 
(for example, crying spells, body aches, low energy or libido, as well as problems 
with eating, weight, or sleeping). The functional changes of clinical depression are 
often called neurovegetative signs. This means that the nervous system changes in 
the brain cause many physical symptoms that result in diminished participation and 
a decreased or increased activity level. 
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Facts 
 Depression is common, affecting about 121 million people 
worldwide. 
 Depression is among the leading causes of disability worldwide. 
 Depression can be reliably diagnosed and treated in primary care. 
 Fewer than 25 % of those affected have access to effective 
treatments. 
 Depression can be reliably diagnosed in primary care. Antidepressant 
medications and brief, structured forms of psychotherapy are effective for 60-80 % 
of those affected and can be delivered in primary care. However, fewer than 25 % of 
those affected (in some countries fewer than 10 %) receive such treatments. 
 In a major medical study, depression caused significant problems in the 
functioning of those affected more often than did arthritis, hypertension, chronic 
lung disease, and diabetes, and in some ways as often as coronary artery disease. 
 Depression can increase the risks for developing coronary artery disease, 
HIV, asthma, and many other medical illnesses. Furthermore, it can increase the 
morbidity (illness/negative health effects) and mortality (death) from these and 
many other medical conditions. 
 Depression can coexist with virtually every other mental health illness, 
aggravating the status of those who suffer the combination of both depression and 
the other mental illness. 
 Depression in the elderly tends to be chronic, has a low rate of recovery, 
and is often undertreated. This is of particular concern given that elderly men, 
particularly elderly white men have the highest suicide rate. 
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Physiology or mechanism40: 
 Depression is thought to arise from changes in substances in the brain 
(neurotransmitters) that help nerve cells communicate, such as serotonin, dopamine 
and norepinephrine. The levels of these neurotransmitters can be influenced by 
genetics, hormonal changes, responses to medications, aging, brain injuries, 
seasonal/light cycle changes, and other medical conditions. The genetic contribution 
to depression is estimated to be 40-50%. Women are twice as likely as men to 
experience depression, perhaps because of fluctuations in hormone levels during the 
menstrual cycle and after childbirth. 
 The Biogenic Amine Hypothesis states that depression is caused by 
monoamines, particularly noradrenaline and serotonin. 
 According to this hypothesis, depression can be alleviated by drugs that 
increase the availability of noradrenaline and serotonin. 
Treatment 
 Antidepressant drugs are thought to work by increasing the amount of 
neurotransmitter in the cleft. They do this by blocking metabolism of monoamines - 
the MAOIs - or by blocking reuptake - the TCAs. Most TCAs are more effective in 
blocking noradrenaline reuptake than serotonin reuptake. 
MAO inhibitors 
 MAOIs were among the first clinically proven antidepressants. Taken 
chronically Drugs which block the metabolism of noradrenaline and serotonin via 
inhibition of MAO are called MAO inhibitors, MAOIs also produce desensitization 
and down-regulation of postsynaptic receptors. MAO degrades neurotransmitters. 
When the action of MAO is blocked, neurotransmitters are not metabolised, so they 
accumulate in the presynaptic neuron 
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1. Nardil 
2. Parnate 
Selective serotonin reuptake inhibitors 
 A serotonin reuptake inhibitor (SRI) is a type of drug which acts as a 
reuptake inhibitor for the neurotransmitter serotonin (5-hydroxytryptamine (5-HT)) 
by blocking the action of the serotonin transporter (SERT). This in turn leads to 
increased extracellular concentrations of serotonin and therefore an increase in 
serotonergic neurotransmission. Most commonly used SRI are 
1. Lexapro  
2. Luvox 
3. Paxil  
4. Prozac 
5. Zoloft  
Tricyclic antidepressants or TCAs. 
 TCAs are effective in blocking the reuptake of noradrenaline and 
serotonin into the presynaptic neuron, they are non-selective: they also block 
postsynaptic receptor sites, including cholinergic (muscarinic), histaminergic, and 
adrenergic receptor sites. Blockade of histaminergic receptors can lead to sedation, 
weight gain, and hypotension. In the elderly, this is a particular problem, since it can 
result in fainting or falls. TCAs also block muscarinic receptors, which can lead to 
blurred vision, dry mouth, constipation, urinary retention, confusion, and delirium, 
some of the most commonly used TCAs are. 
1. Anafranil 
2. Elavil  
3. Endep 
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4. Ludiomil 
5. NorpraminPamelor 
6. Pertofrane 
7. Sinequan 
8. Surmontil 
9. Tofranil 
10. Vivactil 
Serotonin-noradrenaline reuptake inhibitors (SNRIs) 
 The Permissive Hypothesis postulates that low levels of serotonin permit 
abnormal levels of noradrenaline to cause depression or mania. If serotonin cannot 
control noradrenaline, and noradrenaline falls to abnormally low levels, the patient 
becomes depressed. On the other hand, if the level of serotonin falls and the level of 
noradrenaline become abnormally high, the patient becomes manic. 
 According to this hypothesis, antidepressant drugs are effective to the 
degree that they reinstate the ability of serotonin to control noradrenaline, thus 
restoring the critical balance that controls emotional behavior. 
 A new class of antidepressant drugs, work to selectively block reuptake 
of both noradrenaline and serotonin, thereby increasing levels of both monoamines. 
The SNRIs have very little affinity for other postsynaptic receptor sites and are 
therefore less likely to produce some of the side effects associated with TCAs some 
of the most commonly used SNRIs are. 
1. Cymbalta  
2. Effexor  
3. Pristiq 
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DRUG PROFILE41,42,18,40       
 Duloxetine is included in the class of drugs called selective serotonin/ 
norepinephrine reuptake inhibitors (SNRIs). which is used to treat depression, 
anxiety, and other mood disorders. 
Name : Duloxetine hydrochloride 
Synonyms:     N-Methyl-gama-(1-naphthalenyloxy)-2-thiophenepropanamine 
Molecular Structure:    
 
 
     
 
Molecular Formula : C18H19NOS.HCl  
Molecular Weight :   333.88 g/mol 
IUPAC    : (+)-(S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-
2-yl)propan-1-amine 
Mode of action: 
 Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine 
reuptake and a less potent inhibitor of dopamine reuptake. 
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Pka  :  9.34 
Half Life  : 12 hours (range 8-17 hours) 
Absorption :  Orally administered duloxetine hydrochloride is 
well absorbed 
BCS Classification :  CLASS II (Low solubility high permeability) 
Storage  : Store at 25°C (77°F); excursions permitted to 15-
30°C (59-86°F 
Bioavailability :  80% (32% to 80%) 
Protein binding :  95% 
Excretion  :  70% in urine, 20% in feces 
Dosage Forms :  Capsule, coated pellets 
Toxicity  :  Oral, rat LD50: 491 mg/kg for males and 279 
mg/kg for females. Symptoms of overdose include 
tremors, convulsions, reduced activity, slow 
pupillary response, intermittent tremors, and 
rigidity. 
Pharmacology42 
 Duloxetine is in a class of medications called selective serotonin and 
norepinephrine reuptake inhibitors (SSNRIs) and primarily targets major depressive 
disorders (MDD) and stress urinary incontinence (SUI). Duloxetine is also used to 
treat pain and tingling caused by diabetic neuropathy (damage to nerves that can 
develop in people who have diabetes).it is a potent dual inhibitor of serotonin (5-
hydroxytryptamine, 5-HT) and norepinephrine (NE) reuptake, possessing 
comparable affinities in binding to NE and 5-HT transport sites. Interestingly, its 
behaviour contrasts to most other dual-reuptake inhibitors. Furthermore, duloxentine 
lacks affinity for monoamine receptors within the central nervous system. 
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 Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine 
reuptake and a less potent inhibitor of dopamine reuptake. Duloxetine has no 
significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, 
glutamate, and GABA receptors. The antidepressant and pain inhibitory actions of 
duloxetine are believed to be related to its potentiation of serotonergic and 
noradrenergic activity in the CNS. 
Indications18 
 The main uses of duloxetine are in major depressive disorder, general 
anxietydisorder, stress urinary incontinence, painful peripheral neuropathy and 
fibromyalgia. In addition, it is being studied for various other indications. 
Mechanism of Action18 
 Although the exact mechanisms of the antidepressant, central pain 
inhibitory and anxiolytic actions of duloxetine in humans are unknown, these 
actions are believed to be related to its potentiation of serotonergic and 
noradrenergic activity in the CNS. 
Pharmacodynamics18 
 Preclinical studies have shown that duloxetine is a potent inhibitor of 
neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of 
dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, 
adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors in 
vitro. Duloxetine does not inhibit monoamine oxidase (MAO). 
Pharmacokinetics18 
 Duloxetine has an elimination half-life of about 12 hours (range 8 to 17 
hours) and its pharmacokinetics is dose proportional over the therapeutic range. 
Steady-state plasma concentrations are typically achieved after 3 days of dosing. 
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Elimination of duloxetine is mainly through hepatic metabolism involving two P450 
isozymes, CYP1A2 and CYP2D6. 
Absorption and Distribution:  
 Orally administered duloxetine hydrochloride is well absorbed. There is 
a median 2 hour lag until absorption begins (Tlag), with maximal plasma 
concentrations (Cmax) of duloxetine occurring 6 hours post dose. Food does not 
affect the Cmax of duloxetine, but delays the time to reach peak concentration from 
6 to 10 hours and it marginally decreases the extent of absorption (AUC) by about 
10%. There is a 3 hour delay in absorption and a one-third increase in apparent 
clearance of duloxetine after an evening dose as compared to a morning dose. 
 The apparent volume of distribution averages about 1640 L. Duloxetine 
is highly bound (> 90%) to proteins in human plasma, binding primarily to albumin 
and α1-acid glycoprotein. The interaction between duloxetine and other highly 
protein bound drugs has not been fully evaluated. Plasma protein binding of 
duloxetine is not affected by renal or hepatic impairment. 
Metabolism and Elimination43 
 Biotransformation and disposition of duloxetine in humans have been 
determined following oral administration of 14C-labeled duloxetine. Duloxetine 
comprises about 3% of the total radiolabeled material in the plasma, indicating that 
it undergoes extensive metabolism to numerous metabolites. The major 
biotransformation pathways for duloxetine involve oxidation of the naphthyl ring 
followed by conjugation and further oxidation. Both CYP1A2 and CYP2D6 
catalyze the oxidation of the naphthyl ring in vitro. Metabolites found in plasma 
include 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine 
sulfate. Many additional metabolites have been identified in urine, some 
representing only minor pathways of elimination. Only trace (< 1% of the dose) 
amounts of unchanged duloxetine are present in the urine. Most (about 70%) of the 
duloxetine dose appears in the urine as metabolites of duloxetine; about 20% is 
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excreted in the feces. Duloxetine undergoes extensive metabolism, but the major 
circulating metabolites have not been shown to contribute significantly to the 
pharmacologic activity of duloxetine.  
STABILITY DATA37 
 Duloxetine molecule decomposes easily in an acidic environment upon 
formation of a highly toxic naphthol moiety, 60% of API gets degraded in 30min of 
contact with acid. 
 Some degradation product of duloxetinme include “α-napthol’, “4 -
napthol Duloxetine”, “3 -acetyl Duloxetine” 
 The acid degradation of drug data shows that, if the drug reaches the 
stomach in an acidic pH, the drug will easily get decomposed result in the formation 
of toxic substance and reduced bioavailability. Thus the drug should be formulated 
in such a way that it bypasses the gastric fluid and release in small intestine. So as to 
target the small intestine a delayed release formulation has selected.      
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EXCIPIENT PROFILE44 
LACTOSE MONOHYDRATE 
Nonproprietary Names 
 BP :  Lactose monohydrate 
 JP :  Lactose 
 PhEur :  Lactosummonohydricum 
 USPNF :  Lactose monohydrate 
Synonyms 
 Lactose Monohydrate NF, Lactochem coarse crystals, lactochem powder, 
pharmatose DCL 15, pharmatose 50M, HMS coarse powder, NF lactose 310, 
Granulac 70, prismalac 40, Inhalac 70 etc. 
Empirical Formula  
 C12H22O11.H2O 
Molecular Weight 
 360.31 
Structural Formula 
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Description 
 In the solid state, lactose appears as various isomeric forms, depending 
on the crystallization and drying conditions, i.e. α-lactose monohydrate, β-lactose 
anhydrous, and α-lactose anhydrous. Lactose occurs as white to off-white crystalline 
particles or powder. Lactose is odorless and slightly sweet-tasting; α -lactose is 
approximately 20 % as sweet as sucrose, while β-lactose is 40 % as sweet. 
Functional Category 
 Binding agent; diluent for dry-powder inhalers; tablet binder; tablet and 
capsule diluent. 
Applications in Pharmaceutical Formulation or Technology 
1. Lactose is widely used as filler or diluents in tablets and capsules, 
and to a more limited extent in lyophilized products and infant 
formulas.  
2. Lactose is also used as diluents in dry-powder inhalation. Various 
lactose grades are commercially available that have different 
physical properties such as particle size distribution and flow 
characteristics.  
3. Usually, fine grades of lactose are used in the preparation of tablets 
by the wet-granulation method or when milling during processing 
is carried out, since the fine size permits better mixing with other 
formulation ingredients and utilizes the binder more efficiently.  
4. Other applications of lactose include use in lyophilized products, 
where lactose is added to freeze-dried solutions to increase plug 
size and aid cohesion.  
5. Lactose is also used in combination with sucrose (approximately 
1:3) to prepare sugar-coating solutions. Direct-compression grades 
of lactose monohydrate are available as granulated/agglomerated a-
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lactose monohydrate, containing small amounts of anhydrous 
lactose.  
6. Direct-compression grades are often used to carry lower quantities 
of drug and this permits tablets to be made without granulation. 
Other directly compressible lactoses are spray-dried lactose and 
anhydrous lactose. 
Stability and Storage Conditions 
 Mold growth may occur under humid conditions (80 % relative humidity 
and above). Lactose may develop a brown coloration on storage, the reaction being 
accelerated by warm, damp conditions; the purities of different lactose can vary and 
color evaluation may be important, particularly if white tablets are being formulated. 
The color stabilities of various lactoses also differ. Lactose should be stored in a 
well-closed container in a cool, dry place. 
Incompatibilities 
 A Maillard-type condensation reaction is likely to occur between lactose 
and compounds with a primary amine group to form brown, or yellow-brown-
colored products. Lactose is also incompatible with amino acids, aminophylline, 
amphetamines, and lisinopril.  
HYDROXY PROPYL METHYL CELLULOSE 
 Nonproprietary Names 
BP :  Hypromellose 
JP :  Hypromellose 
PhEur :  Hypromellose 
USP :  Hypromellose 
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Synonyms 
 Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; 
Methocel; methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; 
Metolose; Tylopur. 
Molecular Weight 
 Molecular weight is approximately 10,000-1,50,0000.  
Structural Formula 
 
 
 
 
Where R is H, CH3, or CH3CH (OH) CH2 
Description 
 Hypromellose is an odorless and tasteless, white or creamywhite fibrous 
or granular powder. 
Functional Category 
 Bioadhesive material; coating agent, controlled-release agent, dispersing 
agent, dissolution enhancer, emulsifying agent, emulsion stabilizer extended-release 
agent; film-forming agent, foaming agent, granulation aid modified-release agent, 
mucoadhesive, release-modifying agent, solubilizing agent, stabilizing agent, 
suspending agent, sustained-release agent, tablet binder, thickening agent, viscosity-
increasing agent. 
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Applications in Pharmaceutical Formulation or Technology 
1. Hypromellose is widely used in oral, ophthalmic, nasal, and topical 
pharmaceutical formulations. In oral products, hypromellose is 
primarily used as a tablet binder, in film-coating, and as a matrix 
for use in extended release tablet formulations.  
2. Hypromellose is also used in liquid oral dosage forms as a 
suspending and/or thickening agent at concentrations ranging from 
0.25–5.0 %. Hypromellose produces aqueous solutions of greater 
clarity, with fewer undissolvedfibers present, and is therefore 
preferred in formulations for ophthalmic use.   
3. Hypromellose is used as an emulsifier, suspending agent, and 
stabilizing agent in topical gels and ointments. As a protective 
colloid, In addition, hypromellose is used in the manufacture of 
capsules, as an adhesive in plastic bandages, and as a wetting agent 
for hard contact lenses.  
Stability and Storage Conditions 
 Hypromellose powder is a stable material, although it is hygroscopic 
after drying. Solutions are stable at pH 3-11. Increasing temperature reduces the 
viscosity of solutions. Hypromellose undergoes a reversible sol-gel transformation 
upon heating and cooling, respectively. The gel point is 50–900C, depending upon 
the grade and concentration of material. Hypromellose powder should be stored in a 
well-closed container, in a cool, dry place. 
Incompatibilities 
 Hypromellose is incompatible with some oxidizing agents. Since it is 
non-ionic, hypromellose will not complex with metallic salts or ionic organics to 
form insoluble precipitates. 
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SODIUM STARCH GLYCOLATE 
Synonyms 
 Carboxymethyl starch, Explotab, Primojel. 
Functional Category 
 Tablet and capsule disintegrant. 
Description 
 It is white to off-white, odourless, tasteless, free-flowing powder. 
Incompatibilities 
 Incompatible with ascorbic acid 
Stability and Storage 
 It is a stable material. It should be stored in a well closed container to 
protect from wide variations in humidity and temperature that may cause cracking. 
Applications in Pharmaceutical Formulation and Technology 
 As a disintegrant in tablet (wet granulation and direct compression) and 
capsule formulation in 2-8% concentration. 
Micro Crystalline Cellulose 
Non Proprietary Names 
 BP : Microcrystalline Cellulose 
 JP : Microcrystalline Cellulose 
 PhEur : Cellulose, Microcrystalline 
 USP-NF : Microcrystalline Cellulose 
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Synonyms  
Avicel    PH;    Celex;    Cellulose    gel;  hellulosummicrocristallinum; 
Celphere;   Ceolus   KG;   crystalline cellulose; E460; Emcocel; ethispheres 
Structural Formula  
 
 
 
 
Description  
 Microcrystalline cellulose is a purified partially depolymerised cellulose 
that occurs as a white, odourless, tasteless, crystalline powder composed of porous 
particles. It is commercially available in different particle sizes and moisture 
grades that have different   properties and applications.  
Empirical Formula and Molecular Weight  
 (C6H10O5) n 36000 
 where n = 220 
Functional Category   
 Adsorbent,   suspending   agent,  tablet   and   capsule, diluents, tablet 
disintegrant. 
Stability and Storage Conditions 
Microcrystalline cellulose is a stable through hygroscopic material. The 
bulk material should be stored in a well-closed container in a cool, dry place. 
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Incompatibilities  
 Microcrystalline cellulose is a incompatible with strong oxidizing 
agents. 
Applications  
 Microcrystalline cellulose is widely used in pharmaceuticals, primarily as 
a binder/diluents in oral tablet and capsule formulations where it is used in both wet 
granulation  and  direct-compression  processes.  In  addition  to  its  use  as  a 
binder/diluents, microcrystalline cellulose also has some lubricant and 
disintegrantproperties that make it useful in tableting.  
MAGNESIUM STEARATE 
Synonyms: 
 Stearic acid magnesium salt, magnesium salt, magnesium octadecanoate 
Description: 
 It is a fine, white, precipitated of milled, impalpable powder of low bulk  
density, having a faint odor of stearic acid & a characteristic taste. 
Structural Formula: 
 [CH3 (CH2)16COO]2Mg 
Empirical Formula & Molecular Weight: 
 C36H70MgO4  ; 591.34 
Solubility: 
 It is insoluble in water, ethanol & ether, slightly soluble in warm benzene 
& warm ethanol 
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Functional categories: 
 Tablet & capsule lubricant 
Storage: 
Should be stored in well-closed container in a cool, dry place. It is stable    
compound. 
Incompatibilities: 
Incompatible with strong oxidizing agents, strong acids, alkalis &iron  salts. 
It cannot be used in products containing aspirin, some vitamins, &  mostalkaloidal 
salts. 
Applications: 
Used in cosmetics, food & pharmaceutical formulations and as a lubricant      
capsule &table at concentration between 0.25-5.0%. 
Ethylcellulose 
Nonproprietary Names 
 BP :  Ethylcellulose 
 PhEur :  Ethylcellulosum 
 USPNF :  Ethylcellulose 
Synonyms 
 Aquacoat ECD; Aqualon; E462; Ethocel;Surelease. 
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Empirical Formula and Molecular Weight 
 Ethylcellulose with complete ethoxyl substitution (DS = 3) is 
C12H23O6(C12H22O5)nC12H23O5 where n can vary to provide a wide variety of 
molecular weights. Ethylcellulose, an ethyl ether of cellulose, is along-chain 
polymer of b-anhydroglucose units joined together by acetal linkages. 
Functional Category 
 Coating agent; flavoring fixative; tablet binder; tablet filler; viscosity-
increasing agent. 
Applications in Pharmaceutical Formulation or Technology 
 Ethylcellulose is widely used in oral and topical 
pharmaceuticalformulations; The main use of ethylcellulose in oral formulations is 
as ahydrophobic coating agent for tablets and granules. 
 Ethylcellulose coatings are used to modify the release of adrug,(7–10) to 
mask an unpleasant taste, or to improve thestability of a formulation; for example, 
where granules arecoated with ethylcellulose to inhibit oxidation. Modified release 
tablet formulations may also be produced using ethylcellulose as a matrix former. 
 Ethylcellulose, dissolved in an organic solvent or solventmixture, can be 
used on its own to produce water-insoluble films. Higher-viscosity ethylcellulose 
grades tend to produce stronger and more durable films. Ethylcellulose films may be 
modified to alter their solubility,(15) by the addition of hypromellose(16) or a 
plasticizer;(17–19) see Section 18. Anaqueous polymer dispersion (or latex) of 
ethylcellulose such as Aquacoat ECD (FMC Biopolymer) orSurelease (Colorcon) 
may also be used to produce ethylcellulose films without theneed for organic 
solvents. Drug release through ethylcellulose-coated dosage forms can be controlled 
by diffusion through the film coating. This can be a slow process unless a large 
surface area (e.g. pellets orgranules compared with tablets) is utilized. In those 
instances, aqueous ethylcellulose dispersions are generally used to coat granules or 
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pellets. Ethylcellulose-coated beads and granules have also demonstrated the ability 
to absorb pressure and hence protect the coating from fracture during compression. 
Stability and Storage Conditions 
 Ethylcellulose is a stable, slightly hygroscopic material. It is chemically 
resistant to alkalis, both diluteand concentrated, and to salt solutions, although it is 
more sensitive to acidic materials than are celluloseesters. Ethylcellulose is subject 
to oxidative degradation in the presence of sunlight or UV light at elevated 
temperatures. This may be prevented by the use of antioxidant and 
chemicaladditives that absorb light in the 230–340nm range. Ethylcellulose should 
be stored at a temperature notexceeding 328C (908F) in a dry area away from all 
sources of heat. It should not be stored next toperoxides or other oxidizing agents. 
 Incompatibilities 
 Incompatible with paraffin wax and microcrystalline wax. 
Talc 
Nonproprietary Names 
BP :  Purified talc 
JP :  Talc 
PhEur :  Talcum 
USP :  Talc 
Synonyms 
 Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium 
silicate; Luzenac Pharma; magnesium hydrogen metasilicate; MagsilOsmanthus; 
Magsil Star; powdered talc; purified French chalk; Purtalc; soapstone; steatite; 
Superiore. 
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Empirical Formula and Molecular Weight 
 Talc is a purified, hydrated, magnesium silicate, approximating to the 
formula Mg6(Si2O5)4(OH)4. Itmay contain small, variable amounts of aluminum 
silicate and iron. 
Functional Category 
 Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule 
lubricant. 
Applications in Pharmaceutical Formulation or Technology 
 Talc was once widely used in oral solid dosage formulations as a 
lubricant and diluent, although today it is less commonly used. However, it is widely 
used as a dissolution retardant in the development of controlled-release 
products.Talc is also used as a lubricant in tablet formulations; in a novel powder 
coating for extended-release pellets;and as an adsorbant. 
 In topical preparations, talc is used as a dusting powder, although it 
should not be used to dust surgical gloves; Talc is a natural material; it may 
therefore frequently contain microorganisms andshould be sterilizedwhen used as a 
dusting powder;Talc is additionally used to clarifyliquids and is also used 
incosmetics and food products, mainly for its lubricant properties. 
Description 
 Talc is a very fine, white to greyish-white, odorless, impalpable, 
unctuous, crystalline powder. It adheres readily to the skin and is soft to the touch 
and free from grittiness 
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Stability and Storage Conditions 
 Talc is a stable material and may be sterilized by heating at 1608C for 
not less than 1 hour. It may also besterilized by exposure to ethylene oxide or 
gamma irradiation.(10) Talc should be stored in a well-closedcontainer in a cool, dry 
place. 
Incompatibilities 
 Incompatible with quaternary ammonium compounds. 
Triethyl Citrate 
Nonproprietary Names 
BP :  Triethyl citrate 
PhEur :  Triethyliscitras 
USPNF :  Triethyl citrate 
Synonyms 
 Citric acid, ethyl ester; Citroflex 2; Citrofol AI; E1505; Hydagen CAT; 
TEC. 
Empirical Formula and Molecular Weight 
 C12H20O7 276.29 
Functional Category 
 Plasticizer. 
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Applications in Pharmaceutical Formulation or Technology 
 Triethyl citrate and the related esters acetyltriethyl citrate, tributyl citrate, 
and acetyltributyl are used to plasticize polymers in formulated pharmaceutical 
coatings. The coating applications include capsules, tablets, beads, and granules for 
taste masking, immediate release, sustainedrelease,and enteric formulations. 
Triethyl citrate is also used as a direct food additive forflavoring, for solvency, and 
as a surface active agent.  
Description. 
 Triethyl citrate is a clear, odorless,practically colorless, oily liquid. 
Stability and Storage Conditions 
 Triethyl citrate should be stored in a closed container in a cool, dry 
location. When stored in accordancewith these conditions, triethyl citrate is a stable 
product. 
Incompatibilities 
 Triethyl citrate is incompatible with strong alkalis and oxidizing 
materials. 
POLYMETHACRYLATES 
Nonproprietary Names 
BP: Methacrylic acid-ethyl acrylate copolymer (1 : 1) 
PhEur: Acidummethacrylicum et ethylisacrylaspolymerisatum1 : 1 
Acidummethacrylicum et ethylisacrylaspolymerisatum1 : 1 dispersio 30 per centum 
Acidummethacrylicum et methylismethacrylaspolymerisatum1 : 1 
Acidummethacrylicum et methylismethacrylaspolymerisatum1 : 2 
CopolymerummethacrylatisbutylatibasicumPolyacrylatis dispersion 30 per centum 
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USPNF:  Ammonio methacrylate copolymer  
  Methacrylic acid copolymer 
  Methacrylic acid copolymer dispersion 
Synonyms 
 Acryl-EZE; Acryl-EZE MP; Eastacryl 30D; Eudragit; Kollicoat MAE 30 
D; Kollicoat MAE 30 DP; polymeric methacrylates. 
Molecular weight: 
 Typically, the molecular weight of the polymer is-5,10,0000. 
Functional Category 
 Film-forming agent, tablet binder, tablet diluents. 
Applications in Pharmaceutical Formulation or Technology 
 Polymethacrylates are primarily used in oral capsule and tablet 
formulations as film-coating agents. Depending on the type of polymer used, films 
of different solubility characteristics can be produced; Eudragit E is used as a plain 
or insulating film former. It is soluble in gastric fluid below pH 5. In contrast, 
Eudragit L, S and FS types are used as enteric coating agents because they are 
resistant to gastric fluid. Eudragit RL, RS, NE 30D, NE 40D, andNM30D are used 
to form water-insoluble film coats for sustained-release products. Eudragit RL films 
are more permeable than those of Eudragit RS, and films of varying permeability 
can be obtained by mixing the two types together. Eudragit L 30 D-55 is used as an 
enteric coating film former for solid-dosage forms. The coating is resistant to gastric 
juice but dissolves readily at above pH 5.5. Eudragit L 100-55 is an alternative to 
Eudragit L 30 D-55. It is commercially available as a redispersible powder. 
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Stability and Storage Conditions 
 Dry powder polymer forms are stable at temperatures less than 3080C. 
Above this temperature, powders tend to form clumps, although this does not affect 
the quality of the substance and the clumps can readily be broken up. Dry powders 
are stable for at least 3 years if stored in a tightly closed container at less than 
3080C.  
 Dispersions are sensitive to extreme temperatures and phase separation 
occurs below 00C. Dispersions should therefore be stored at temperatures between 5 
and 2580C and are stable for at least 18 months after shipping from the 
manufacturers warehouse if stored in a tightly closed container at the 
aboveconditions. 
Incompatibilities 
 Incompatibilities occur with certain polymethacrylate dispersions 
depending upon the ionic and physical properties of the polymer and solvent. For 
example, coagulation may be causedby soluble electrolytes, pH changes, some 
organic solvents, and extremes of temperature; For example, dispersions of Eudragit 
L 30 D, RL 30 D, L 100-55, and RS 30 D are incompatible with magnesium 
stearate. Eastacryl 30D, Kollicoat MAE 30 D, and Kollicoat MAE 30 DP are also 
incompatible with magnesium stearate. Interactions between polymethacrylates and 
some drugs can occur, although solid polymethacrylates and organic solutions are 
generally more compatible than aqueous dispersions. 
POVIDONE K-30 
Synonyms:  
 Kollidon,Plasdone,polyvinylpyrrolidone,  
Empirical Formula and Molecular Weight:  
 (C6H9NO)n& 50,000 
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Functional Category:  
 Disintegrant, Dissolution enhancer, Suspending agent, Tablet binder. 
Applications in Pharmaceutical Formulation or Technology:  
 Povidone is additionally used as a suspending, stabilizing, or viscosity-
increasing agent in a number of topical and oral suspensions and solutions. The 
solubility of a number of poorly soluble active drugs may be increased by mixing 
with povidone. 
Description:  
 Povidone occurs as a fine, white to creamy-white colored, odorless or 
almost odorless, hygroscopic. 
Stability and Storage Conditions:  
 Povidone may be stored under ordinary conditions without undergoing 
decomposition or degradation. However, since the powder is hygroscopic, it should 
be stored in an airtight container in a cool, dry place. 
Incompatibilities:  
 Povidone is compatible in solution with a wide range of inorganic salts, 
natural and synthetic resins, and other chemicals. 
Hydroxypropyl Cellulose 
Nonproprietary Names 
BP :  Hydroxypropylcellulose 
JP :  Hydroxypropylcellulose 
PhEur :  Hydroxypropylcellulosum 
USPNF :  Hydroxypropyl cellulose 
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Synonyms 
 Cellulose, hydroxypropyl ether; E463; hyprolose; Klucel;Methocel; 
Nisso HPC; oxypropylated cellulose. 
Empirical Formula and Molecular Weight 
 The PhEur 2005 and USPNF 23 describe hydroxypropylcellulose as a 
partially substituted poly(hydroxypropyl) etherof cellulose. It may contain not more 
than 0.6% of silica or another suitable anticaking agent. Hydroxypropyl cellulose 
iscommercially available in a number of different grades thathave various solution 
viscosities. Molecular weight has a range of 50 000–1 250 000. 
Functional Category 
 Coating agent; emulsifying agent; stabilizing agent; suspendingagent; 
tablet binder; thickening agent; viscosity-increasingagent. 
Applications in Pharmaceutical Formulationor Technology 
 Hydroxypropyl cellulose is widely used in oral and 
topicalpharmaceutical formulations, In oral products, hydroxypropyl cellulose is 
primarily usedin tableting as a binder,(1) film-coating,(2) and extended-
releasematrixformer.(3–5) Concentrations of hydroxypropyl cellulose of 2–6% w/w 
may be used as a binder in either wet-granulationor dry, direct-compression 
tableting processes.(6–10) Concentrationsof 15–35% w/w of hydroxypropyl 
cellulose may be usedto produce tablets with an extended drug release. Therelease 
rate of a drug increases with decreasing viscosity ofhydroxypropylcellulose.In 
topical formulations,hydroxypropyl cellulose is used in transdermal patches 
andophthalmic preparations. Hydroxypropyl cellulose is also used in cosmetics and 
infood products as an emulsifier and stabilizer. 
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Description 
 Hydroxypropyl cellulose is a white to slightly yellow-colored,odorless 
and tasteless powder.  
Stability and Storage Conditions 
 Hydroxypropyl cellulose powder is a stable material, althoughit is 
hygroscopic after drying. 
 Aqueous solutions of hydroxypropyl cellulose are stable atpH 6.0–8.0, 
with the viscosity of solutions being relativelyunaffected. However, at low pH 
aqueous solutions may undergo acid hydrolysis, resulting in chain scission and 
hencea decrease in solution viscosity. The rate of hydrolysis increaseswith 
increasing temperature and hydrogen ion concentration. 
 At high pH, alkali-catalyzed oxidation may degrade thepolymer and 
result in a decrease in viscosity of solutions.Hydroxypropyl cellulose powder should 
be stored in a wellclosed container in a cool, dry place. 
Incompatibilities 
 Hydroxypropyl cellulose in solution demonstrates someincompatibility 
with substituted phenol derivatives, such asmethylparaben and propylparaben. The 
presence of anionic polymers may increase the viscosity of hydroxypropyl 
cellulosesolutions. 
 The compatibility of hydroxypropyl cellulose with inorganicsalts varies 
depending upon the salt and its concentration 
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Sodium Alginate 
Nonproprietary Names 
BP :  Sodium alginate 
PhEur :  Natriialginas 
USPNF :  Sodium alginate 
 Synonyms 
 Algin; alginic acid, sodium salt; E401; Kelcosol; Keltone; Protanal; 
sodium polymannuronate. 
Empirical Formula and Molecular Weight 
 Sodium alginate consists chiefly of the sodium salt of alginicacid, which 
is a mixture of polyuronic acids composed ofresidues of D-mannuronic acid and L-
guluronic acid. 
Functional Category 
 Stabilizing agent; suspending agent; tablet and capsule disintegrant; 
tablet binder; viscosity-increasing agent. 
Applications in Pharmaceutical Formulation or Technology 
 Sodium alginate is used in a variety of oral and topicalpharmaceutical 
formulations.(2) In tablet formulations, sodiumalginate may be used as both a binder 
and disintegrant;(3) it has been used as a diluent in capsule 
formulations.Sodiumalginate has also been used in the preparation of 
sustainedreleaseoral formulations since it can delay the dissolution of a drug from 
tablets,capsules, and aqueous suspensions.In topical formulations, sodium alginate is 
widely used as athickening and suspending agent in a variety of pastes, creams,and 
gels, and as a stabilizing agent for oil-in-water emulsions. 
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 Description 
 Sodium alginate occurs as an odorless and tasteless, white topale 
yellowish-brown colored powder. 
Stability and Storage Conditions 
 Sodium alginate is a hygroscopic material, although it is stableif stored at 
low relative humidities and a cool temperature.Sodium alginate solutions are 
susceptible on storage to microbial spoilage, which may affect solution 
viscosity.Solutions are ideally sterilized using ethylene oxide, althoughfiltration 
using a 0.45 mm filter also has only a slight adverse effect on solution viscosity 
Incompatibilities 
 Sodium alginate is incompatible with acridine derivatives,crystal violet, 
phenylmercuric acetate and nitrate, calcium salts,heavy metals, and ethanol in 
concentrations greater than 5%. 
 Low concentrations of electrolytes cause an increase in viscositybut high 
electrolyte concentrations cause salting-out of sodiumalginate; salting-out occurs if 
more than 4% of sodium chlorideis present 
Hypromellose Acetate Succinate 
Nonproprietary Names 
USPNF: Hypromellose acetate succinate 
Synonyms 
Aqoat; Aqoat AS-HF/HG; Aqoat AS-LF/LG; Aqoat AS-MF/ 
MG; cellulose, 2-hydroxypropyl methyl ether, acetate succinate; 
HPMCAS. 
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Empirical Formula and Molecular Weight 
Hypromellose acetate succinate is a mixture of acetic acid and monosuccinic 
acid esters of hydroxypropylmethyl cellulose. 
The molecular weight of hypromellose acetate succinate is approximately 55 
000–93 000 Daltons. 
Functional Category 
Component of controlled-release or sustained-release dosage forms; enteric 
coating agent; film-forming agent; solid dispersion vehicle. 
Applications in Pharmaceutical Formulation or Technology 
Hypromellose acetate succinate is commonly used in oral pharmaceutical 
formulations as a film coating, as well as enteric coating material for tablets or 
granules.(5–7) It is insoluble in gastric fluid but will swell and dissolve rapidly in 
the upper intestine. For aqueous film-coating purposes, a dispersion of hypromellose 
acetate succinate fine powder and triethyl citrate (as a plasticizer) in water is 
commonly utilized.(4,8,9) Organic solvents can also be used as vehicles for 
applying this polymer as a film coating. 
Description 
Hypromellose acetate succinate is a white to off-white powder or 
granules.(4) It has a faint acetic acid-like odor and a barely detectable taste. 
Hypromellose acetate succinate is available in several grades, according to the pH at 
which the polymer dissolves (low, L; medium, M; and high, H) and its predominant 
particle size (cohesive fine powder, F; or freeflowing granules, G). 
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Stability and Storage Conditions 
Hypromellose acetate succinate should be stored in a wellclosed container, 
in a cool, dry place. In such storage conditions, hypromellose acetate succinate is a 
stable material. 
It is stable for four years after manufacturing. Hypromellose acetate 
succinate is hygroscopic. It is hydrolyzed to acetic acid and succinic acid, and the 
hypromellose polymer starts to form if dissolved in 1 mol/L sodium hydroxide for 
more than twohours. The hydrolysis is the main degradation pathway that is 
responsible for increasing amounts of free acids in storage, especially upon exposure 
to moisture.Hypromellose Acetate Succinate  
Incompatibilities 
Hypromellose acetate succinate is incompatible with strong acids or bases, 
oxidizing agents, and sustained levels of elevated humidity. 
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SUITABILITY OF DRUG 
1. Duloxetine is a selective serotonin/nor-epinephrine reuptake 
inhibitor (SNRI) which is used to treat depression, anxiety, and 
other mood disorders. 
2. Duloxetine Hydrochloride is acid instable drug; it degrades rapidly 
in acidic environment to form its inactive and toxic metabolites.  
3. So to make drug better available in body and to decrease its 
degradation and impurity levels the drug must be formulated as a 
delayed release formulation to improve its bioavailability. 
4. Multiparticulate systems-Because of their smaller particle size 
compared to single unit dosage forms these systems are capable of 
passing through the upper GI tract easily, and reach the intestine 
quickly and retained longer time thus, a multiparticulate system of 
delayed release formulation is suitable for Duloxetine 
Hydrochloride. 
5. Programmable oral drug absorption system (PRODAS) is a type of 
multiparticulate system, where a number of mini tablets filled in 
hard gelatin capsule. Thus it combines the benefits of tableting 
technology within a capsule. Compared to other multiparticulate 
systems (for ex: pellets) production of mini tablets is as simple as 
conventional tablets and it is economic, low cost production, no 
need of advanced technology & trained personals, though we can 
get the same benefits as that of pellets, thus a programmable oral 
drug absorption system (mini tablets) of delayed release 
formulation is suitable for Duloxetine Hydrochloride. 
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AIM AND OBJECTIVE OF WORK 
 The aim of the present study is to develop and evaluate a delayed release 
oral capsule comprising Duloxetine Hydrochloride mini tablets 60mg strength with 
various enteric coating polymers with the following objectives 
1. To study the Drug-Excipient compatibility. 
2. To minimize the drug release in stomach (acidic environment) 
thereby reduce the formation of metabolite and increase the 
bioavailability. 
3. To develop a formulation which is similar in dissolution profile and  
there by establishing similarity to that of the reference product 
CYMBALTA 
4. To develop a cost effective medicine when compare to marketed 
product. 
5. To improve patient compliance. 
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PLAN OF WORK 
1.  Collection of innovator product details 
2.  To carry out the pre formulation studies of API. 
a. Description 
b. Bulk density, Tapped density. 
c. Flow properties 
d. Angle of repose 
e. Car's index 
f. Hausner's ratio 
g. Particle size distribution by mechanical sieve shaker. 
h. Solubility studies (pH solubility profile) 
i. Water content by Karl Fisher method 
j. Moisture pickup study 
k. Drug-Excipient compatibility study by FT-IR 
3.  Analytical method development  
a. Determination of  ʎmax. 
b. Determination of calibration curve. 
4.  To take batches to optimize the formulation ingredients and 
 develop final formulation. 
 Steps involved in formulation development of Duloxetine Hcl DR 
  capsules 
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 Step-I: Compression of core mini tablets.. 
 Step-II: Barrier coating of core mini tablets 
 Step-III: Enteric coating 
5.  Results and discussion 
6.  Conclusion. 
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MATERIALS & METHODS 
Table No.2 List of Excipients used 
S.NO INGREDIENTS CATEGORY 
1 Minrocrystalline cellulose PH102 Diluent 
2 Lactose mono hydrate Diluent 
3 Klucel Binder 
4 Sodium starch glycolate Disintegrent 
5 Magnesium stearate Lubricant 
6 HPMC 3cps Binder 
7 Talc Opacifier 
8 Purified water Solvent 
9 Acryleze MP Enteric coating polymer 
10 PVP K30 Binder 
11 HPMC AS MF Enteric coating polymer 
12 TEC Placticizer 
13 NS enteric Enteric coating polymer 
14 Surelase Enteric coating polymer 
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Instrument and Apparatus used  
Table No.3 List of  Instruments used 
S.NO INSTRUMENT MAKE 
1 COATING PAN SAMS TECHNOMECH 
2 DIGITAL WEIGHING BALANCE SHIMADZU 
3 SHIFTER SAMS TECHNOMECH 
4 ROTARY COMPRESSION MACHINE CADMECH 
5 FRIABILATOR ELECTROLAB 
6 VERNIER CALIPER MITUTIYO 
7 MECHANICAL STIRRER REMI MOTOR 
8 HARDNESS TESTER VARIAN 
9 DISINTEGRATION TEST 
APPARATUS 
ELCTROLAB 
10 TRAY DRYER GANSONS 
INSTRUMENT USED IN ANALYSIS 
1 PH METER THERMOORION 
2 DISSOLUTION APPARATUS ELECTROLAB 
3 UV APPARATUS SHIMADZU 
4 SONICATOR ENERTECH 
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METHODS USED 
1.  Compression of core mini tablets 
 The direct compression method has been selected for compression of 
 core mini tablets as it is simple, easy, convenient, suitable and more 
 economic. 
2.  Dissolution Studies (pH dissolution profiling) 
 Based on the pharmacokinetics and physico-chemical characteristics of 
the API the following dissolution method was selected for the reference 
product characterisation and further product development. 
A. Gastric challenge: 
 USP I, 100 rpm, 1000ml 0.1N HCl for 2 hours and the mini tablets were 
 assayed for drug content.  
B. Dissolution (0.1N HCl followed by pH 6.8 Phosphate buffer) 
 USP I, 100 rpm, 1000ml 0.1N HCl for 2 hours followed by 1000ml pH 
 6.8 Phosphate buffer, sampling at 15, 30, 45, 60, 90 and 120 min. 
Dissolution media preparation: 
a) 0.1N Hydrochloric acid USP 
 8.5 g of concentrated hydrochloric acid is made up to 1000 ml with 
 purified water. 
b) pH 6.8 Phosphate buffer USP 
 6.8 gm of potassium dihydrogen phosphate is mixed with 1000ml of 
 water and the pH was adjusted to 6.8 using dilute NaOH solution. 
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EXPERIMENTATION 
 
PRE FORMULATION STUDIES 
1.  Description 
 Duloxetine Hydrochloride is a white to off white powder 
2.  Bulk Density  
 Duloxetine Hydrochloride was analyzed for apparent and tap density. 
This was determined by using Erweka Tap density apparatus. Results are presented 
below. 
Table No 4: Bulk Density 
Bulk Density (gm/cc) 0.220 
Tap Density (gm/cc) 0.460 
 
3.  Solubility Studies (pH Solubility profile) 
 Solubility of Duloxetine Hydrochloride was analyzed in various media at 
different pH. The data is presented below. 
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Table No 5: Solubility Profile 
Medium 
Solubility 
(mg/ml) 
Quantity/250ml 
Purified Water 50.40 12.60 gm 
0.001N Hydrochloric 
acid 
53.70 13.42 gm 
pH 4.5 Acetate buffer 57.92 14.48 gm 
pH 5.5 Acetate buffer 110.23 27.55 gm 
pH 6.8 Phosphate 
buffer 
4.25 1.06 gm 
 
 Above data shows that quantity of drug dissolved in 250ml media is 
more than the highest dose, 60mg. Hence, Duloxetine Hydrochloride can be 
classified as ‘Highly soluble’ across all the pH ranges as per the BCS. 
4. Particle Size Distribution 
 Particle size analysis was determined by using laser diffraction method 
and the results are presented below Instrument used: Malvern apparatus 
Table No 6: Particle Size Distribution 
Batch Number DTMU080004 DTMU080005 
D50  6µm 6µm 
D90  15µm 16µm 
 
 
 
73 
 
 Experimentation 
5.  Water content by Karl Fisher Method: 
 Water content of two different batches of Duloxetine Hydrochloride was 
determined by Karl fisher titration and the results are presented below. 
Table No 7: Water Content of API 
Batch Number Water by KF 
DTMU080001 0.18(%w/w) 
DTMU080002 0.22(%w/w) 
 
6.  Moisture Pick up Study: 
 Moisture pickup study of API was carried out at different relative 
humidity conditions maintained at 25±2°C. Moisture sorption at different humidity 
conditions was determined by weight method 
Table No 8: Moisture Pick up Study 
Time 
(hours) 
Condition 
43%RH 60%RH 75%RH 
% Sorption 
4 -0.03 0.01 0.02 
16 -0.08 0.00 0.04 
24 -0.11 -0.01 0.05 
48 -0.11 -0.02 0.05 
72 -0.11 -0.01 0.05 
 
 The results reveals that the API has not picked any moisture thus it is 
concluded that Duloxetine hydrochloride is non hygroscopic 
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7  carrs index:  
 Compressiblity is the ability of the Powder to decrease in volume under 
pressure. Using untapped density. The percentage compressibility was determind 
which is given as cars compressibility Index. 
 CI  = Vi – V0/Vi x 100 
 Where CI  =  Compressibility Index  
 V0  = Bulk density  
 Vi  = Tapped density 
 Compressibility Index = 52.17  
8 Hausner Ratio 
 It is measurement of frictional resistance of the drug. It was determind by 
the ratio of tapped density & bulk density. 
 Hausner Ratio = 𝑽𝑽𝑽𝑽
𝑽𝑽𝑽𝑽
 
where  𝑉𝑉0
𝑉𝑉𝑉𝑉
 = bulkdensity /tapped density 
9 Angle of reporse  
Angle of reporse is the maximum angle formed between the surface of pile of 
powder and horizontal plane. It is usually determined by fixed funnel method and is 
the ability to measure the flowability of powder  
  θ= tan-1 (h/r) 
H =height of the heap of the pile 
R= radius of the base of the pile 
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             Angle of Reporse =44.6 
10. Drug excipient compatibility:   
 The drug excipient compatibility was performed for 4 weeks at 40±2°C/ 
75±5% RH. The samples were packed in self seal poly bag. The list of excipients 
taken & its corresponding ratio were given in the table below. 
Table No 9: Drug excipient ratio 
S NO DRUG + EXCIPIENTS RATIO 
1 Duloxetine hydrochloride (API) 1:1 
2 API + Micro crystalline cellulose 1:1 
3 API + Lactose 1:1 
4 API + Eudragit L100 55 1:1 
5 API + HPMC Acetate succinate  1:1 
6 API + Sodium starch glycolate 1:1 
7 API + Talc 1:1 
8 API + Magnesium. Stearate 1:1 
9 API + Tri Ethyl Citrate 1:1 
10 API + Povidone 1:1 
11 API + Hydroxy propyl cellulose  1:1 
12 API + Hydroxy propyl methyl  cellulose 1:1 
13 API + NS enteric  1:1 
14 API + Surelase 1:1 
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Table No 10: Drug excipient compatibility 
  
S NO 
  
composition  Physical observation Water by 
K/F 
1 
 
Duloxetine hydrochloride (API) 
 
Initial White powder 0.35 
4W 40°C/75 No change  0.37 
2 
 
API + Micro crystalline cellulose 
Initial White powder   4.72 
4W 40°C/75 No change   4.62 
3 
 
API + Lactose 
Initial White powder   4.44 
4W 40°C/75  Dull colour 4.39 
4 
 
API + Eudragit L100 55 
 
Initial  White powder  3.63 
4W 40°C/75  Pink colour 3.59 
5 
API + HPMC AS 
 
Initial  White powder  2.17 
4W 40°C/75  Ash colour 2.41 
6 
API + HPMC E5 LV 
 
Initial White powder   3.70 
4W 40°C/75 No change    4.05 
7 
API + Sodium starch glycolate 
 
Initial White powder 3.12 
4W 40°C/75 No change 4.65 
8 
API + Talc 
 
Initial White powder   0.35 
4W 40°C/75  No change   0.61 
9 
API + Magnesium Stearate 
Initial White powder   1.64 
4W 40°C/75  No change   1.74 
10 
API + Tri Ethyl Citrate 
Initial  White paste 0.58 
4W 40°C/75  No change   0.97 
11 
API + Povidone 
Initial White powder   0.28 
4W 40°C/75 No change    1.24 
12 
 
API + Hydroxy propyl cellulose 
Initial  White powder  0.12 
4W 40°C/75  No change   1.23 
13 
 
API + NS Enteric 
Initial  White powder  0.11 
4W 40°C/75 No change   1.35 
14. 
API + Surelase 
Initial  White powder  0.17 
4W 40°C/75 No change   1.27 
 
 
77 
 
 Experimentation 
ANALYTICAL METHOD DEVLOPMENT 
DETERMINATION OF λ max: 
 Preparation of stock solution: 1mg/ml stock solution of Duloxetine 
hydrochloride is prepared by dissolving 100mg in 100 ml of pH 6.8 phosphate 
buffer. A 3 µg/ml test solution is prepared and the maximum absorbance is checked 
from 400-200nm.  
The λ max is found to be 218nm. 
 
Fig 9 λ max of duloxetine 
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DETERMINATION OF CALIBRATION CURVE: 
 A series of test solution containing 1µg/ml, 2µg/ml, 3µg/ml, 
4µg/ml,5µg/ml of Duloxetine hydrochloride is prepared using the above stock 
solution and the absorbance was checked at  218  nm 
Table No 11: Calibration Curve 
CONCENTRATION ABSORBENCE 
0 0 
1 0.1997 
2 0.3784 
3 0.5647 
4 0.7584 
5 0.9247 
 
 
Fig 10: Calibration Curve 
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FORMULATION DEVELOPMENT 
 Formulation development of Duloxetine Hcl delayed release capsule 
containing mini tablets Formulation of dulolxetineHcl mini tablets includes 
following steps 
Stage 1: Direct compression of Mini tablets 
 It involves direct compression of Duloxetine Hcl lubricated blend 
Stage 2: Barrier coating of mini tablets 
 It involves 20% barrier coating on the core mini tablet. 
Stage3: Enteric coating of barrier coated mini tablets 
 The process of enteric coating includes spraying of enteric polymer on 
the barrier coated of mini tablets. 
 The three enteric coating polymers used are 
1. Acryleze MP 
2. Hydroxy propyl methyl cellulose acetate succinate MF  
3. Sureteric and NS Enteric(25:75) 
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STAGE 1: DIRECT COMPRESSION OF MINI TABLETS 
Table No: 12 Formula For Direct Compression Of Mini Tablets 
S.No Ingredients 
For One Mini  
Tablet(mg) 
For One 
Capsule(mg) 
1 Duloxetine Hcl 16.83 67.3 
2 
Minrocrystalline 
cellulose PH102 
18.9 75.6 
3 Lactose Monohydrate 18.9 75.6 
4 Klucel 3.0 12 
5 Sodium starch glycolate 1.8 7.2 
6 Magnesium Stearate 0.6 2.4 
 
 16.83 mg of Duloxetine Hcl is equal to 15mg of Duloxetine 
 67.30 mg of Duloxetine Hcl is equal to 60mg of Duloxetine 
Procedure: 
1) All the ingredients were accurately weighed and passed through 
ASTM#40 mesh except magenesium stearate.  
2) The above material was prelubricatedin a  polybag for 20minutes 
3) Then  Magnesium stearate was passed  through ASTM #60 mesh 
4) Then Magnesium stearate was added  and the above blend was 
lubricated for 5 minutes in a  polybag 
5) Then it was compressed by using multi tip  punch tooling (4.5mm) 
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Compression parameters: 
Table No: 13 Compression Parameters For Direct Compression Of Mini Tablets 
Weight of the tablets 240 mg ± 7.5 % 
Hardness 4.0 – 4.7 kP 
Disintegration time 2- 2.5 minutes 
Thickness 3.3 – 3.4 mm 
 
 STAGE II: BARRIER COATING 
 Barrier coating was done on the core mini tablets to avoid the interaction 
of drug with the enteric  polymer. Due to acidic nature of enteric coating it will react 
with the drug and cause incompatibility therefore barrier coating was applied. 
Criteria for the selection of barrier coating material: 
1)  Excipient with low free acid content 
2)  Non hygroscopic material 
Table No: 14 Formula For Optimisation Of Barrier Coating. 
S.No Ingredients mg/unit 
F1 F2 F3 F4 
1 Drug mini tablets 240 240 240 240 
2 Hydroxypropylmeth-ylcellulose 3cps 19.2 19.2 19.2 19.2 
3 Talc 28.8 28.8 28.8 28.8 
4. Purified water q.s q.s q.s q.s 
5. Tablet Wt. per unit capsule 288 288 288 288 
     30 % overages.solid content 15 % w/w 
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Procedure 
 Preparation of barrier coating suspension 
 Accurate quantity of HPMC 3cps was weighed and then added to 
purified water under vortex  and  was stirred to dissolve it and get a clear solution.  
 Weighed quantity of talc was added and stirred to get a homogeneous 
suspension. Then the  suspension was passed through ASTM#40 mesh 
Coating of barrier suspension: 
  The tablets were taken and prewarmed for ten mins and then barrier 
coating solution was sprayed and coating was done with below mentioned process 
parameters 
Table No: 15 Process Parameters For Barrier Coating 
Atomisation  pressure 1.1  bar 
Inlet Temperature 42ºC 
Pan Rpm 22-25 RPM 
Bed Temperature 36 
Spray Rate 4-8gm/min 
Process Time 4 hrs 
 
STAGE 3: ENTERIC COATING 
 Duloxetine hcl degrades in the acidic environment so it is important to by 
pass the acidic pH of the stomach. Protection of the drug from acidic environment 
and promoting the drug release in the intestinal pH enteric coating of the drug was 
attempted.  
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Strategy: 
 Different build ups of enteric coating with Acryleze MP, HPMCAS MF, 
and sureteric and NS enteric  was done and each batch was evaluated based on its 
gastric resistance and drug release in pH 6.8 phosphate buffer.  
Optimization of Enteric coating build up with Acryleze MP 
Method: 
 Enteric coating suspension with varying quantity of AcrylezeMP  
polymer , Enteric coating suspension   was prepared and coated on barrier coated 
mini tablets the formula for enteric coating with acrylase MP is given below. 
Table No: 16 Formula For Optimization Of Enteric Coating Build Up With 
Acryleze Mp 
S.No Ingredients F1-(20%) 
(mg) 
 F2-(25%) 
(mg) 
F3- (30%) 
(mg) 
1 Barrier coated mini 
tablets 
288 288 288 
2 Acryleze MP 53.856 66.96 80.352 
3 PVP K30 3.73824 4.608 5.616 
4 Purified water 345.6 360 374.4 
 Tab wt per capsule 336 350 364 
*20 % overages   15 % w/wsolid content 
Procedure: 
Preparation of enteric coating suspension: 
1)  The purified water was divided in to two equal parts. 
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2)   Povidone K30 wasaccurately weighed and addedto  purified water 
under vortex and was  stirred to get a clear solution. 
3)  Acryleze MP wasaccurately weighed and added to the above 
soltution  and was  stirred for 45 minutes to get a uniform 
dispersion. 
4)   Both were mixed and stirred to get a uniform dispersion. 
5)   The above enteric coating suspension was sprayed on barrier coated 
mini tablets using conventional coating pan. 
Process parameters : 
Table No: 17 Process Parameter For Entering Coating With Acryleze Mp 
Inlet Temperature 36-38ºC 
Bed  Temperature 32 ºC 
RPM 20-25 minutes 
Atomization pressure 1.1  bar 
Process time  4hrs 
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OPTIMIZATION OF ENTERIC COATING BUILD UP WITH  
HYDROXY PROPYL METHYLCELLULOSE ACETATE 
SUCCINATE MF 
Strategy: 
 To take batches with different build up of enteric coating with Hydroxy 
propyl methyl cellulose acetate succinate MF and to finalize the build up on the 
basis of acid resistance and dissolution (Acid followed by pH  6.8 Phosphate 
buffer). 
Method:  
 Enteric coating suspension with varying quantity of HPMC AS MF 
polymer, Enteric coating  suspension were prepared and coated on barrier coated 
mini tablets the formula for enteric coating with HPMC AS MF is given below. 
Table No 18: Formula For Optimization Of Enteric Coating Build Up With  
Hydroxy Propyl Methylcellulose Acetate Succinate Mf 
S.No Ingredients F1-(20%) 
(mg) 
 F2-(25%) 
(mg) 
 F3-(30%) 
(mg) 
1 Barrier coated mini 
tablets 
288 288 288 
2 HPMC AS MF 41.15 51.44 61.72 
3 TEC 20% 8.22 10.28 12.33 
4 Talc 30% 12.34 15.43 18.51 
5 Purified water q.s q.s q.s 
 Tablet wt/unit capsule 336 350 364 
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Procedure: 
Preparation of enteric coating suspension: 
1)  Tri Ethyl Citrate was added to purified water and stirred for 10 
 minutes  
2)  HPMC AS MF was added to the above solution and talc was 
 gradually added  and stirred for 20minutes 
3)  Thenthe above suspension was passed through ASTM#40 
4)  28%w/v of NaoH solution was prepared  and neutralization was 
 started. 
5)   The above enteric coating suspension was sprayed on barrier coated 
 mini tablets using conventional coatingpan 
Process parameters: 
Table  No: 19 Process Parameter For Enteric Coating With Hpmc As Mf 
Inlet Temperature 40-45ºC 
Bed  Temperature 32 ºC 
RPM 20-25 minutes 
Atomization pressure 1.1  bar 
Process time 5hrs 
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OPTIMIZATIONS OF ENTERIC COATING BUILD UP WITH SURETERIC 
AND NS ENTERIC: 
Strategy:  
 To take batches with different build up of enteric coating with Sureteric 
And NS Enteric and to finalise the build up on the basis of acid resistance and 
dissolution (Acid followed by pH  6.8 Phosphate buffer). 
Method:  
 Enteric coating suspension with varying quantity of Sureteric And NS 
Enteric were prepared and enteric coating suspension was coated on barrier coated 
mini tablets the formula for enteric coating with Sureteric And NS Enteric is given 
below. 
Table No: 20 Formula For Optimizations Of Enteric Coating Build Up With 
Sureteric And Ns Enteric 
S.No Ingredients F1-(2%) 
(mg) 
 F2-(4%) 
(mg) 
 F3-(6%) 
(mg) 
1 Barrier coated mini 
tablets 
288 288 288 
2 NS Enteric 4.32 8.64 12.96 
3 Sureteric 1.44 2.88 4.32 
4 Purified water q.s q.s q.s 
 Tablet wt/unit capsule 285.6 291.2 296.8 
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Procedure: 
 Accurately weighed quantity of NS enteric was added to the required 
quantity of purified water and stirred for 20 minutes  
 Accurately weighed quantity of Surelasedispersion(containing 30% 
solids) was added and stirred for 20 minutes The above preparations was mixed and 
stirred for 30 mins to get a uniform suspension  
 Then the  above suspension was passed through ASTM#40 mesh  
Process parameters: 
Table No: 21  Process parameter for entering coating with Sureteric and NS 
Enteric 
Inlet Temperature 40-45ºC 
Bed  Temperature 32 ºC 
RPM 20-25 minutes 
Atomization pressure 1.1  bar 
Process time 5hrs 
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RESULTS & DISCUSSION 
Preformulation studies 
Table No: 22 Characterization of API 
S.No Characteristics Results 
1 Description White to off white powder 
2 Solubility Soluble in ph 6.8 phosphate 
buffer,very soluble in 
methanol,sparingly soluble in 
water 
3 Bulk Density 0.220gm/cc 
4 Tapped Density 0.460 gm/cc 
5 Carrs index 52.17 
6 Haushner ratio 1.02 
7 Angle of 
reporse 
44.6 
 
From the above results it has been concluded that API has poor flow property 
Evaluation of mini tablets 
Table no 23: Evaluation of Mini Tablets 
S.NO WEIGHT 
VARIATION 
(mg) 
HARDNESS 
(Kp) 
THICKNESS 
(mm) 
DISINTEGRATION 
TIME (mins) 
1 60 4.1 3.30 2 min 10 sec 
2 59 4.2 3.33 2 min 18 sec 
3 59 4.0 3.40 2 min 13 sec 
4 61 4.5 3.36 2 min 21 sec 
5 60 4.7 3.32 2 min 26 sec 
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6 59 4.4 3.35 2 min 28 sec 
7 61 4.2 3.37 2 min 27 sec 
8 60 4.1 3.30 2 min 19 sec 
9 60 4.7 3.31 2 min 14 sec 
10 60 4.4 3.36 2 min 21 sec 
11 61 4.6 3.38 2 min 26 sec 
12 61 4.2 3.37 2 min 27 sec 
13 60 4.4 3.31 2 min 29 sec 
14 58 4.3 3.32 2 min 20 sec 
15 60 4.1 3.35 2 min 21 sec 
16 61 4.5 3.31 2 min 18 sec 
17 60 4.1 3.36 2 min 26 sec 
18 61 4.2 3.36 2 min 27 sec 
19 62 4.5 3.39 2 min 24 sec 
20 60 4.6 3.38 2 min 31 sec 
 
Friability:  
 5 sets of tablets were taken and friability tests were conducted in 
rochefriabilator and the results are given below 
Table No: 24 Friability Values of Mini Tablets 
S.NO FRIABILITY (%) 
SET 1 0.35 
SET 2 0.56 
SET 3 0.45 
SET 4 0.60 
SET 5 0.40 
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Assay:  
 The mini tablets were assayed for drug content after under going 
dissolution at USP 1 (basket) at 100 rpm, 1000ml, 0.1N Hcl for 2hrs and the values 
are given  
Table No: 25 Assay Values of Mini Tablets 
S.No Formulation Assay value 
1 F1 99.7±0.1 
 
 
BARRIER COATING: 
 Barrier coating is done to prevent the interaction between the drug and 
enteric coating material.The 20% of barrier coating was optimized through stability 
studies. 
RESULTS FOR OPTIMISATIONS OF ENTERIC COATING BUILD UP 
WITH ACRYLEZE MP: 
 Tooptimize the build up of enteric coating with Acryleze MP different 
trials were taken & it is evaluated on the basis of acid release & dissolution. The 
results are presented below. 
Dissolution (0.1N HCL followed by pH 6.8 phosphate buffer) 
 USP1 (Basket),100RPM  ,1000ml 0.1N HCL for 2 hours followed by 
1000ml pH 6.8 phosphate buffer and sampling is done at time intervals of 
15,30,45,60,90, 120 minutes. 
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 Results & Discussion 
Table No: 26 Effect of enteric coating build up on dissolution of batch made 
with Acryleze MP. 
TIME F1 (20%) F2 (25%) F3 (30%) 
ACID RELEASE 
120 0 0 0 
pH 6.8 PHOSPHATE BUFFER 
135 54 55 45 
150 74 75 52 
165 79 82 65 
180 80 92 72 
210 84 96 78 
240 86 98 83 
 
 
Figure 11: Effect of enteric coating build up with Acryleze MP on dissolution 
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 Results & Discussion 
DISCUSSION: 
 From the above results is clearly evident that the batch made up with 
25% enteric coating of Acryleze MP shows higher similarity factor with the 
innovator product dissolution and it was found to be better than other batches 
dissolution. The batch with 20% build up shows no acid release but the dissolution 
got hampered. But batch with 25% showed better dissolution profiling then 20% and 
30%. All the 3 batches have passed in gastric resistance. The process with Acryleze 
MP aqueous suspension was found to be efficient and it is economical and safe.  
RESULTS FOR OPTIMISATIONS OF ENTERIC COATING BUILD UP 
WITH HPMC AS MF: 
 Tooptimize the build up of enteric coating with HPMC AS MF different 
trials were taken & it is evaluated on the basis of acid release & dissolution. The 
results are presented below. 
Dissolution (0.1N HCL followed by pH 6.8 phosphate buffer) 
 USP1 (Basket),100RPM  ,1000ml 0.1N HCL for 2 hours followed by 
1000ml pH 6.8 phosphate buffer and sampling is done at time intervals of 
15,30,45,60,90, 120 minutes 
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 Results & Discussion 
Table No: 27Effect of enteric coating build up on dissolution of batch made 
with HPMC AS MF. 
TIME F1 (20%) F2 (25%) F3 (30%) 
                                    ACID RELEASE 
120 0 0 0 
                      pH 6.8 PHOSPHATE BUFFER 
135 38 30 27 
150 70 62 58 
          165 86 76 71 
180 94 83  78 
210 97 93 82 
240 99 96 89 
 
 
Figure: 12 Effect of enteric coating build up on dissolution of batch made with 
HPMC AS MF. 
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 Results & Discussion 
DISCUSSION 
 From the above results is clearly evident that the batch made up with 
20% enteric coating of HPMC AS MF shows highest similarity factor with the 
innovator product and it was found to be better than other batches dissolution. The 
batch with 25% build up shows no acid release but the dissolution got hampered. 
But batch with 20% showed better dissolution profiling then 25% and 30%. All the 
3 batches have passed in gastric resistance. The process with HPMC AS MF Non 
aqueous suspension was found to be critical due to fine generation and consumption 
of huge quantity of solvent. 
RESULTS FOR OPTIMISATIONS OF ENTERIC COATING BUILD UP 
WITH SURETERIC AND NS ENTERIC: 
 Tooptimize the build up of enteric coating with SURETERIC AND NS 
ENTERIC different trials were taken & it is evaluated on the basis of acid release & 
dissolution. The results are presented below. 
Dissolution (0.1N HCL followed by pH 6.8 phosphate buffer) 
 USP1 (Basket),100RPM  ,1000ml 0.1N HCL for 2 hours followed by 
1000ml pH 6.8 phosphate buffer and sampling is done at time intervals of 
15,30,45,60,90, 120 minutes 
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 Results & Discussion 
Table No: 28 Effect of enteric coating build up on dissolution of batch made 
with SURETERIC AND NS ENTERIC 
TIME F1 (2%) F2 (4%) F3 (6%) 
                                    ACID RELEASE 
120 0 0 0 
                      pH 6.8 PHOSPHATE BUFFER 
135 28 24 21 
150 36 32 30 
165 54 46 42 
180 74 63 59 
210 79 69 61 
240 88 79 72 
 
 
Figure:13 Effect of enteric coating build up on dissolution of batch made with 
SURETERIC AND NS ENTERIC 
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 Results & Discussion 
DISCUSSION: 
   The batch made up with 2% enteric coating of sureteric and NS enteric 
shows good dissolution profile than other batches dissolution when compared to 
innovator product.The batch with 2% build up shows no acid release but the 
dissolution got hampered. But batch with 4% and 6% showed low dissolution 
profile .All the 3 batches have passed in gastric resistance. The process with 
SURETERIC AND NS ENTERIC aqueous suspension was found to be efficient and 
it is economical and safe.  
PHARMACEUTICAL EQUIVALENCE STUDIES: 
REFERENCE AND IN HOUSE PRODUCT CHARACTERIZATION: 
Table No: 29 Reference and in House Product Characterization: 
PARAMETERS REFERENCE PRODUCT       IN HOUSE PRODUCT 
Description 
Opaque green body and 
opaque blue cap, and is 
imprinted with “60 mg” on the 
body and “LILLY 3237” on 
the cap 
Blue cap/Green body, Size 1, 
hard gelatin capsule, imprinted 
with “OHC” on cap with white 
ink and “60mg” on body with 
black ink, filled with white to off 
white pellets 
Fill weight (mg) 332.5  343.45 
Assay 101.3 %  99.80% 
Water by KF 2.0 %   2.4% 
Acid stage release of Cymbalta® delayed release capsules 60 mg 
 The acid stage release of Cymbalta® delayed release capsules 60 mg is 
presented  below 
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 Results & Discussion 
Medium  : 0.1N Hcl 
Dissolution type : USP I (Basket) 
RPM   : 100 
Media Volume : 1000ml 
Table: 30 Acid Stage Release Of Reference Product 
Time 
Cymbalta® delayed release capsules 60mg Average % 
Drug 
released % Drug released  
Unit 1 Unit 2 Unit 3 
1.57 2 hours 0.9 2 1.8 
 
 Dissolution profile in 0.1N HCl for 2 hours followed by pH 6.8 
Phosphate buffer 
 Medium :  0.1N HCl for 2 hours followed by pH 6.8 
Phosphate buffer 
 Dissolution type :  USP I (Basket) 
 RPM :  100 
 Media Volume :  1000ml 
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 Results & Discussion 
Table No: 31Dissolution of Reference Product at Ph 6.8 Phosphate Buffer 
Time Cymbalta® delayed release capsules 60mg 
Average % 
drug dissolved 
(min.) Cumulative % drug dissolved 
  Unit 1 Unit 2 Unit 3 
15 36.3 40.4 38.4 38.37 
30 66.5 70.4 68.3 68.4 
45 78.5 82.6 81.6 80.9 
60 84.3 88.5 86.5 86.44 
90 90.8 93.7 92.2 92.24 
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 Results & Discussion 
Table no:32 Comparative desolution profile of innovator produst with different 
buid up of enteric coated polymers used. 
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 Results & Discussion 
Discussion: 
On the basis of results obtained for acid release and dissolution profile of the 3 
enteric coating polymers made with different build ups Acryleze MP 25% was 
found to have highest similarity with the innovator product and as it is a aqueous 
base and economical and safe compared to other formulations Acryleze MP 25% 
was selected as optimized formulation  
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 Results & Discussion 
Table no.33 Comparative Dissolution Profile of Marketed Product and 
Developed Product 
TIME MARKETED PRODUCT DEVELOPED PRODUCT 
0 0 0 
120 0 0 
135 41 55 
150 78 75 
165 90 82 
180 95 92 
210 96 96 
240 98 98 
 
 
Comparative Dissolution Profile of Marketed Product and Developed Product 
 
 
-20
0
20
40
60
80
100
120
0 50 100 150 200 250
%
 d
ru
g 
R
el
ea
se
Time in Mins
Comparitive Dissolution Profile of Marketed Product 
and Developed Product 
MARKETED PRODUCT DEVELOPED PRODUCT
103 
 
 Results & Discussion 
DISCUSSION 
 The comparative study of developed product with the marketed product 
shows that both are pharmaceutically equivalent  
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 Conclusion 
 
CONCLUSION 
 Duloxetine hydrochloride is an acid labile drug which degrades at the 
acidic pH of the stomach so duloxetine hydrochloride multi particulate has been 
designed as gastroresistant mini tablets. The preformulation studies of Duloxetine 
hydrochloride including the drug excipient compatibility has been conducted and the 
formulation is developed in such a way to release the drug in small intestine and 
keep the formulation stable for a long time. 
 Multiparticulate formulation has enormous advantages over all other oral 
dosage forms, especially in modified release formulation thus Duloxetine is made as 
multiparticulate drug delivery system. And the formulation is made in fluidised bed 
processor (wurster process), using bottom spray. 
 The enteric system  of duloxetine was evaluated with 3 polymers with 
various percentage build ups and evaluated for acid resistance  and dissolution 
profile The initial result indicates, the product is having good acid resistant, when it 
exposed to acidic environment, and having good dissolution profile in pH 6.8 
phosphate buffer, and comparable to the marketed formulation. 
Stability study is initiated. 
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